

**mice.** R6/2 mice at P7 were injected with AAV5-GFP on one side of the striatum and AAV5-QBP1 on the other side, and at 4, 8, and 14 weeks of age htt inclusion body formation in virus infected neurons of the striatum (left) and cortex (right) was assessed by immunohistochemistry. Data are shown as means  $\pm$  SEM of  $\geq 6$  fields of view, in which over 180 cells were counted ( $*p < 0.05$ ,  $***p < 0.001$ ). Representative results of two mice analyzed are shown.

(PDF)

**Figure S3 AAV5 “infected” and “non-infected” cells can be clearly distinguished from their fluorescence intensity.** The fluorescence intensity of representative cells that were regarded as either “infected” or “non-infected” in photographs of immunostained brain sections of R6/2 mice injected with either AAV5-GFP (left), AAV5-QBP1 (middle) or AAV5-

Hsp40 (right). For each sample, a total of over 100 representative cells were analyzed from 5–6 fields of view.

(PDF)

## Acknowledgments

We thank Kenzo Ohtsuka for the human Hsp40 cDNA, Yoshinaga Saeki and Hirokazu Hirai for helpful discussions, and Reiko Sasaki, Hirokazu Matsushima, Naomi Takino, Hitomi Miyauchi, and Keiko Ayabe for their technical assistance.

## Author Contributions

Conceived and designed the experiments: HAP T. Takeuchi SM T. Toda KW YN. Performed the experiments: HAP T. Takeuchi HF KY CI HY. Analyzed the data: HAP T. Takeuchi T. Toda KW YN. Contributed reagents/materials/analysis tools: SM. Wrote the paper: HAP T. Takeuchi YN.

## References

- Gusella JF, MacDonald ME (2000) Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. *Nat Rev Neurosci* 1: 109–115.
- Orr HT, Zoghbi HY (2007) Trinucleotide repeat disorders. *Annu Rev Neurosci* 30: 575–621.
- Michalik A, Van Broeckhoven C (2003) Pathogenesis of polyglutamine disorders: aggregation revisited. *Hum Mol Genet* 12 Spec No2: R173–186.
- Shao J, Diamond MI (2007) Polyglutamine diseases: emerging concepts in pathogenesis and therapy. *Hum Mol Genet* 16 Spec No.2: R115–123.
- Nagai Y, Popiel HA (2008) Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed  $\beta$ -sheet hypothesis. *Curr Pharm Des* 14: 3267–3279.
- Williams AJ, Paulson HL (2008) Polyglutamine neurodegeneration: protein misfolding revisited. *Trends Neurosci* 31: 521–528.
- Bauer PO, Nukina N (2009) The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. *J Neurochem* 110: 1737–1765.
- Aguzzi A, Rajendran L (2009) The transcellular spread of cytosolic amyloids, prions, and prionoids. *Neuron* 64: 783–790.
- Brunin P, Melki R, Kopito R (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. *Nat Rev Mol Cell Biol* 11: 301–307.
- Lee SJ, Desplats P, Sigurdson C, Tsigenly I, Masliah E (2010) Cell-to-cell transmission of non-prion protein aggregates. *Nat Rev Neurol* 6: 702–706.
- Frost B, Diamond MI (2010) Prion-like mechanisms in neurodegenerative diseases. *Nat Rev Neurosci* 11: 155–159.
- Bates G (2003) Huntingtin aggregation and toxicity in Huntington's disease. *Lancet* 361: 1642–1644.
- Herbst M, Wanker EE (2006) Therapeutic approaches to polyglutamine diseases: combating protein misfolding and aggregation. *Curr Pharm Des* 12: 2543–2555.
- Nagai Y, Tucker T, Ren H, Kenan DJ, Henderson BS, et al. (2000) Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. *J Biol Chem* 275: 10437–10442.
- Nagai Y, Inui T, Popiel HA, Fujikake N, Hasegawa K, et al. (2007) A toxic monomeric conformer of the polyglutamine protein. *Nat Struct Mol Biol* 14: 332–340.
- Popiel HA, Burke JR, Strittmatter WJ, Oishi S, Fujii N, et al. (2011) The aggregation inhibitor peptide QBP1 as a therapeutic molecule for the polyglutamine neurodegenerative diseases. *J Amino Acids* 2011: 265084.
- Nagai Y, Fujikake N, Ohno K, Higashiyama H, Popiel HA, et al. (2003) Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in *Drosophila*. *Hum Mol Genet* 12: 1253–1259.
- Liberek K, Lewandowska A, Zietkiewicz S (2008) Chaperones in control of protein disaggregation. *EMBO J* 27: 328–335.
- Kampinga HH, Craig EA (2010) The HSP70 chaperone machinery: J proteins as drivers of functional specificity. *Nat Rev Mol Cell Biol* 11: 579–592.
- Hard FU, Bracher A, Hayer-Hartl M (2011) Molecular chaperones in protein folding and proteostasis. *Nature* 475: 324–332.
- Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, et al. (1999) Suppression of polyglutamine-mediated neurodegeneration in *Drosophila* by the molecular chaperone HSP70. *Nat Genet* 23: 425–428.
- Kazemi-Esfarjani P, Benzer S (2000) Genetic suppression of polyglutamine toxicity in *Drosophila*. *Science* 287: 1837–1840.
- Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, et al. (2000) Identification of genes that modify ataxin-1-induced neurodegeneration. *Nature* 408: 101–106.
- Chan HY, Warrick JM, Gray-Board GL, Paulson HL, Bonini NM (2000) Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in *Drosophila*. *Hum Mol Genet* 9: 2811–2820.
- Satyal SH, Schmidt E, Kitagawa K, Sondheimer N, Lindquist S, et al. (2000) Polyglutamine aggregates alter protein folding homeostasis in *Caenorhabditis elegans*. *Proc Natl Acad Sci USA* 97: 5750–5755.
- Cummings CJ, Sun Y, Opal P, Antalfy B, Mestril R, et al. (2001) Overexpression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. *Hum Mol Genet* 10: 1511–1518.
- Adachi H, Katsuno M, Minamiyama M, Sang C, Pagoulatos G, et al. (2003) Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. *J Neurosci* 23: 2203–2211.
- Hansson O, Nylandsted J, Castilho RF, Leist M, Jaattela M, et al. (2003) Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. *Brain Res* 970: 47–57.
- Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, et al. (2004) Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. *Hum Mol Genet* 13: 1389–1405.
- Labbadia J, Novoselov SS, Bett JS, Weiss A, Paganetti P, et al. (2012) Suppression of protein aggregation by chaperone modification of high molecular weight complexes. *Brain*.
- Okada T, Nomoto T, Shimazaki K, Lijun W, Lu Y, et al. (2002) Adeno-associated virus vectors for gene transfer to the brain. *Methods* 28: 237–247.
- Davidson BL, Breakefield XO (2003) Viral vectors for gene delivery to the nervous system. *Nat Rev Neurosci* 4: 353–364.
- Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. *Cell* 87: 493–506.
- Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, et al. (1994) Convection-enhanced delivery of macromolecules in the brain. *Proc Natl Acad Sci USA* 91: 2076–2080.
- Hageman J, Rujano MA, van Waarde MA, Kakkar V, Dirks RP, et al. (2010) A DNABP chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. *Mol Cell* 37: 355–369.
- Ross CA, Poirier MA (2005) Opinion: What is the role of protein aggregation in neurodegeneration? *Nat Rev Mol Cell Biol* 6: 891–898.
- Howarth JL, Kelly S, Keasey MP, Glover CP, Lee YB, et al. (2007) Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease. *Mol Ther* 15: 1100–1105.
- Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, et al. (2010) A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. *Mol Ther* 18: 1731–1735.
- Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, et al. (2009) Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. *Nat Cell Biol* 11: 219–225.
- Herrera F, Tenreiro S, Miller-Fleming L, Outeiro TF (2011) Visualization of cell-to-cell transmission of mutant huntingtin oligomers. *PLoS Curr* 3: RRN1210.
- Goodenough DA, Paul DL (2009) Gap junctions. *Cold Spring Harb Perspect Biol* 1: a002576.
- Calderwood SK, Mambula SS, Gray PJ, Jr., Theriault JR (2007) Extracellular heat shock proteins in cell signaling. *FEBS Lett* 581: 3689–3694.
- Bauer PO, Goswami A, Wong HK, Okuno M, Kurosawa M, et al. (2010) Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. *Nat Biotechnol* 28: 256–263.
- Ohtsuka K (1993) Cloning of a cDNA for heat-shock protein hsp40, a human homologue of bacterial DnaJ. *Biochem Biophys Res Commun* 197: 235–240.



## Analyses of the *MAPT*, *PGRN*, and *C9orf72* mutations in Japanese patients with FTLD, PSP, and CBS

Kotaro Ogaki<sup>a</sup>, Yuanzhe Li<sup>b</sup>, Masashi Takanashi<sup>a</sup>, Kei-Ichi Ishikawa<sup>a</sup>, Tomonori Kobayashi<sup>d</sup>, Takashi Nonaka<sup>e</sup>, Masato Hasegawa<sup>e</sup>, Masahiko Kishi<sup>f</sup>, Hiroyo Yoshino<sup>b</sup>, Manabu Funayama<sup>a,b</sup>, Tetsuro Tsukamoto<sup>g</sup>, Keiichi Shioya<sup>h</sup>, Masayuki Yokochi<sup>i</sup>, Hisamasa Imai<sup>a</sup>, Ryogen Sasaki<sup>j</sup>, Yasumasa Kokubo<sup>j</sup>, Shigeki Kuzuhara<sup>k</sup>, Yumiko Motoi<sup>a</sup>, Hiroyuki Tomiyama<sup>a,c</sup>, Nobutaka Hattori<sup>a,b,c,\*</sup>

<sup>a</sup> Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan

<sup>b</sup> Research Institute for Diseases of Old Age, Juntendo University School of Medicine, Tokyo, Japan

<sup>c</sup> Department of Neuroscience for Neurodegenerative Disorders, Juntendo University School of Medicine, Tokyo, Japan

<sup>d</sup> Department of Neurology, Fukuoka University School of Medicine, Fukuoka, Japan

<sup>e</sup> Department of Neuropathology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

<sup>f</sup> Department of Internal Medicine, Division of Neurology, Sakura Medical Center, Toho University, Sakura, Japan

<sup>g</sup> Department of Neurology, Numazu Rehabilitation Hospital, Numazu, Japan

<sup>h</sup> Department of Neurology, National Hospital Organization Miyazaki Higashi Hospital, Miyazaki, Japan

<sup>i</sup> Department of Neurology, Tokyo Metropolitan Health and Medical Treatment Corp., Ebara Hospital, Tokyo, Japan

<sup>j</sup> Department of Neurology, Mie University Graduate School of Medicine, Tsu, Mie, Japan

<sup>k</sup> Department of Medical Welfare, Faculty of Health Science, Suzuka University of Medical Science, Suzuka, Mie, Japan

### ARTICLE INFO

#### Article history:

Received 26 April 2012

Received in revised form

16 June 2012

Accepted 19 June 2012

#### Keywords:

*MAPT*

*PGRN*

*C9orf72*

De novo

Abnormal eye movements

### ABSTRACT

**Background:** Mutations in the microtubule associated protein tau (*MAPT*) and progranulin (*PGRN*) have been identified in several neurodegenerative disorders, such as frontotemporal lobar degeneration (FTLD), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS). Recently, *C9orf72* repeat expansion was reported to cause FTLD and amyotrophic lateral sclerosis (ALS). To date, no comprehensive analyses of mutations in these three genes have been performed in Asian populations. The aim of this study was to investigate the genetic and clinical features of Japanese patients with *MAPT*, *PGRN*, or *C9orf72* mutations.

**Methods:** *MAPT* and *PGRN* were analyzed by direct sequencing and gene dosage assays, and *C9orf72* repeat expansion was analyzed by repeat-primed PCR in 75 (48 familial, 27 sporadic) Japanese patients with FTLD, PSP, or CBS.

**Results:** We found four *MAPT* mutations in six families, one novel *PGRN* deletion/insertion, and no repeat expansion in *C9orf72*. Intriguingly, we identified a *de novo* *MAPT* p.S285R mutation. All six patients with early-onset PSP and the abnormal eye movements that are not typical of sporadic PSP had *MAPT* mutations. The gene dosages of *MAPT* and *PGRN* were normal.

**Discussion:** *MAPT* p.S285R is the first reported *de novo* mutation in a sporadic adult-onset patient. *MAPT* mutation analysis is recommended in both familial and sporadic patients, especially in early-onset PSP patients with these abnormal eye movements. Although *PGRN* and *C9orf72* mutations were rare in this study, the *PGRN* mutation was found in this Asian FTLD. These genes should be studied further to improve the clinicogenetic diagnoses of FTLD, PSP, and CBS.

© 2012 Published by Elsevier Ltd.

\* Corresponding author. Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113-8421, Japan. Tel.: +81 3 5802 1073; fax: +81 3 5800 0547.

E-mail address: [nhattori@juntendo.ac.jp](mailto:nhattori@juntendo.ac.jp) (N. Hattori).

### 1. Introduction

Mutations in the microtubule-associated protein tau (*MAPT*) and the progranulin (*PGRN*) genes have been identified in families with frontotemporal dementia and parkinsonism linked to chromosome 17 [1–3]. Recently, two studies reported that the expansion of a noncoding GGGGCC hexanucleotide repeat in the *C9orf72* gene is

a major cause of both frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) [4,5].

Each of these genes can be associated with multiple clinical entities. Patients with *MAPT* mutations may receive diagnoses of frontotemporal dementia (FTD), primary progressive aphasia (PPA), or progressive supranuclear palsy (PSP). Rarely, corticobasal syndrome (CBS) or FTD with ALS (FTD-ALS) may be manifested in these patients [6]. The clinical diagnoses of patients with *PGRN* mutations include FTD, PPA, and CBS [6]. *C9orf72* repeat expansion causes FTD, ALS, FTD-ALS [4,5], PPA [5,7], and CBS [8] phenotypes. Thus, due to the complicated and often overlapping genetic and phenotypic variability in these patients, an accurate diagnosis of these clinical entities before autopsy is often difficult for clinicians.

To date, few comprehensive screening studies of these three genes have been performed in Asian populations. The aims of this study are to characterize the roles of known and, more importantly, novel disease-causing genes and to investigate the genetic and clinical features of FTLD, PSP, and CBS patients with *MAPT*, *PGRN*, and *C9orf72* mutations. In this study, we also describe the abnormal eye movements that are generally not observed in sporadic PSP but occur in early-onset PSP patients bearing *MAPT* mutations.

## 2. Methods

### 2.1. Subjects

We studied 75 Japanese patients who were diagnosed with FTLD, PSP, and CBS with or without a family history of disease. FTLD was divided into three subclasses: behavioral variant FTD (bvFTD), FTD-ALS, and PPA. The clinical diagnoses were established according to the consensus criteria for FTD [9], PPA [10], PSP [11], and CBS [12]. The characteristics of the 75 analyzed patients (69 index patients) are shown in Table 1. This study was approved by the ethics committee of the Juntendo University School of Medicine. Each subject provided written informed consent. All of the subjects in the control cohort were Japanese individuals and were evaluated by neurologists to ensure that no subjects exhibited any clinical manifestations of neurodegenerative diseases.

### 2.2. Genetic analyses

For direct sequence analysis, each exon was amplified by polymerase chain reaction (PCR) using published primers for *MAPT* [13] and *PGRN* [2] in a standard protocol. Dideoxy cycle sequencing was performed using Big Dye Terminator chemistry (Applied Biosystems, Foster City, CA). These products were loaded into ABI310 and 3130 automated DNA sequence analyzers and analyzed with DNA Sequence Analysis software (Applied Biosystems). To provide a qualitative assessment of the presence of an expanded (GGGGCC)<sub>n</sub> hexanucleotide repeat in the *C9orf72* gene, we performed repeat-primed PCR as previously described [4]. The normal repeat number of the GGGGCC hexanucleotide was determined in all of the patients using genotyping primers, as previously described [4]. The PCR products

**Table 1**  
The clinical diagnoses and characteristics of 75 patients (69 index patients).

Clinical phenotype	No.	% of total	% of Male	Mean (SD) AAO (range, years)	Familial	Sporadic
FTLD	38	50.7	39.5	57.1 (±12.4), 36–78	21	17
bvFTD	29	38.7	34.5	54.5 (±12.6), 36–78	18	11
FTD-ALS	2	2.7	100	67.5 (±1.5), 66–69	1	1
PPA	7	9.3	42.9	65.0 (±7.4), 58–77	2	5
PSP	25	33.3	68.0	59.8 (±13.0), 40–76	18	7
CBS	12	16.0	33.3	58.4 (±9.52), 40–71	9	3
Total	75	100	48.0	58.2 (±12.3), 36–78	48	27
Index patients	69	92.0	46.4	58.9 (±12.4), 36–78	42	27
Relatives	6	8	66.7	50.3 (±6.6), 44–61	6	0

FTLD = frontotemporal lobar degeneration.

bvFTD = behavioral variant frontotemporal dementia.

FTD-ALS = frontotemporal dementia with amyotrophic lateral sclerosis.

PPA = primary progressive aphasia; PSP = progressive supranuclear palsy.

CBS = corticobasal syndrome; SD = standard deviation; AAO = age at onset.

were analyzed on an ABI3130 DNA Analyzer and visualized using Gene Mapper software (Applied Biosystems).

### 2.3. Multiplex ligation-dependent probe amplification (MLPA)

To confirm the gene dosages of *MAPT* and *PGRN*, we performed MLPA using the SALSA MLPA P275-B1 *MAPT*-*PGRN* kit (MRC-Holland, Amsterdam, The Netherlands). The DNA detection/quantification protocol was provided by the manufacturer. The products were quantified using the ABI3130 Genetic Analyzer and Gene Mapper v3.7 (Applied Biosystems). The kit contains 32 probes, including 13 *MAPT* probes (located in exons 1–13) and 5 *PGRN* probes (located in exons 1, 3, 6, 10, and 12) located within other genes on chromosome 17q21. The MLPA data were analyzed as described previously [14].

### 2.4. Exon-trapping analysis

To determine whether a novel *MAPT* mutation was pathogenic, we performed an exon-trapping analysis. We used a wild-type construct and constructs containing the novel *MAPT* p.S285R or the IVS10+3 intronic mutation [15]. The *MAPT* sequences included exon 10, 34 nucleotides of the upstream intronic sequence and 85 nucleotides of the downstream intronic sequence. The PCR products were subcloned into the splicing vector pSPL3 (Invitrogen, Carlsbad, CA), and exon trapping was performed as described previously [15].

### 2.5. Paternity testing

Microsatellite analysis with 10 markers (D2S293, D3S3521, D4S2971, D5S495, D6S16171, D7S2459, D8S1705, D16S430, D18S450, and D20S842) was performed in Patient 1 and his parents to confirm paternity.

### 2.6. TA cloning

The novel *PGRN* heterozygous deletion/insertion found in this study, *PGRN* p.G338RfsX23 (c.1012\_1013delGGinsC), was confirmed by cloning the PCR products into the pCR4-TOPO Vector using the TOPO TA Cloning kit (Invitrogen) and sequencing the two haplotypes of the heterozygote.

## 3. Results

### 3.1. Results of *MAPT* analysis

#### 3.1.1. Genetic and molecular analyses of *MAPT*

In this study, we identified nine patients with *MAPT* mutations from six families. Four heterozygous missense mutations in *MAPT*, p.L266V, p.N279K, p.N296N, and the novel p.S285R (Supplementary Fig. 1), were identified by direct sequencing. None of the 182 normal Japanese controls included in this study had the *MAPT* p.S285R. In addition, we examined the amino acid sequences of the *MAPT* protein in other species and found that the site of the p.S285R mutation was highly conserved (see Supplementary Fig. 2). The novel p.S285R mutation in *MAPT* was detected in Patient 1 but not in his parents (Fig. 1A and Supplementary Fig. 1). The parentage of this patient and the DNA authenticity were confirmed using a microsatellite panel (see Supplementary Table 1). These results suggest that p.S285R is a *de novo* mutation. To investigate whether the p.S285R mutation is pathogenic, we performed an exon-trapping analysis. The p.S285R mutation produced a marked increase in the splicing of exon 10 (Fig. 1B) and resulted in the overproduction of tau isoforms that contain 4-repeat tau, such as IVS10+3 [15]. These results indicate that the p.S285R mutation is a novel, *de novo* pathogenic mutation. Previously, p.L266V, p.N279K, and p.N296N had been reported as pathogenic mutations [16–18].

Table 2 lists the clinical features of all of the *MAPT*- and *PGRN*-positive patients in this study, and Supplementary Fig. 3 shows Pedigrees C, D, E, F, and G. The average age at disease onset of patients with a single heterozygous *MAPT* mutation was 42.3 ± 2.9 (range: 37–46) years. MLPA analysis showed no gene dosage abnormalities (multiplications or deletions) in *MAPT* in this cohort.




Fig. 1. (A) The pedigrees of families A and B. (B) Exon-trapping analysis for the effects of the *MAPT* p.S285R mutation on exon 10 splicing. (C) Horizontal electro-oculogram recordings in Patient 2.

### 3.1.2. Clinical presentations of *MAPT*-positive patients with the abnormal eye movements that are generally not observed in patients with sporadic PSP

**3.1.2.1. Patient 1 (*MAPT* p.S285R).** This patient was a 46-year-old man who presented with difficulty speaking and breathing. The patient had no family history of dementia or movement disorders (Fig. 1A). A physical examination revealed gait disturbance, limb bradykinesia, and frequent falling. At age 47, the patient exhibited palilalia and a mild obsession with eating. The patient's Mini-Mental State Examination (MMSE) score was 28/30, but his Frontal Assessment Battery score was 12/18. The patient exhibited a slowing of saccadic eye movements with a relative preservation of smooth pursuit, vertical supranuclear gaze palsy, and tonic upward ocular fixation (see Video Supplement); when the patient's eyes opened after closing, they remained fixated upward and could not be moved voluntarily to the primary position (i.e., Bell's phenomenon remained). To overcome this disability, the patient extended his neck, which resulted in a reflex downward movement of the eyes (the vestibulo-ocular reflex), and next he slightly flexed his neck to a neutral position with his eyes in the primary position. Later, the patient developed bradykinesia and postural instability with frequent falling. *L*-dopa/benserazide (up to 900 mg/day) was ineffective. The patient's condition gradually deteriorated, and he developed dementia, retrocollis, vertical and horizontal supranuclear palsy, and bradykinesia. At age 49, the patient died of suffocation from the aspiration of food material. No autopsy was performed. The clinical diagnosis was probable PSP.

**3.1.2.2. Patient 2 (*MAPT* p.N279K).** This patient was the older brother of Patient 3 (Fig. 1A). Patient 2 was a 42-year-old man who exhibited oscillopsia, micrographia, and a shuffling gait. This patient reported having had nystagmus without oscillopsia since childhood. A neurological examination revealed marked horizontal nystagmus. The patient's pupils were isocoric, and his visual acuity was normal. The patient presented with rigidity, bradykinesia, and postural tremor in the upper limbs. Electro-oculography revealed horizontal pendular nystagmus in the primary position and in all gaze directions (Fig. 1C). *L*-dopa/benserazide at 200 mg/day mildly alleviated his parkinsonism. Two years later, the patient developed prominent postural instability and became prone to falling. Upward and downward gaze palsy and apraxia of eyelid opening were also noted. At that time, the clinical diagnosis was possible PSP with

a family history of dementia and parkinsonism. The patient's cognitive function deteriorated gradually. At age 52, he was bedridden and required a gastrostomy. The patient died of pneumonia at age 54. A postmortem pathological examination of the brain revealed mild atrophy of the frontal lobe and the tegmentum of the midbrain and pons. Microscopic analysis showed severe degenerative changes in the substantia nigra and the subcortical nuclei. Immunohistochemistry using anti-phosphorylated tau (p-tau) antibodies revealed numerous tau-positive neuronal and glial inclusions in the frontotemporal cortex, white matter, and the subcortical nuclei (see Supplementary Fig. 4). These p-tau deposits reacted with anti-4-repeat tau antibodies but not with anti-3-repeat tau antibodies.

**3.1.2.3. Patient 3 (*MAPT* p.N279K).** This patient was the younger brother of Patient 2 (Fig. 1A). At age 44, Patient 3 noticed clumsiness in his right hand and oscillopsia. The patient reported having nystagmus since childhood. A neurological examination revealed large, horizontal pendular nystagmus in the primary position and in all gaze directions. The patient's visual acuity, pupils, and light reflexes were all normal. Mild bradykinesia and rigidity in the neck and the right upper limb were noted. Postural tremor in both hands and the tongue and postural instability were observed. Treatment with 600 mg/day of *L*-dopa/carbidopa was not effective. The patient's oscillopsia gradually worsened, and eventually he was unable to read printed materials. At age 47, the patient developed upward and downward gaze palsy, slowing of saccades, and apraxia of eyelid opening. The patient had prominent postural instability and was prone to falling. The patient's first clinical diagnosis was possible PSP with a family history of dementia and parkinsonism. The patient died at age 56. An autopsy was not performed.

**3.1.2.4. Patients 5, 6, and 7 (*MAPT* p.N279K).** The clinical presentations of these three patients have been described previously [19]. All three patients had clinical diagnoses of possible PSP (Table 2) and visual grasping [19,20].

## 3.2. Results of PGRN analysis

### 3.2.1. Genetic Analyses of PGRN

We identified one patient with a PGRN mutation (Table 2, Supplementary Fig. 3). One novel heterozygous deletion/insertion

**Table 2**  
Clinical features of patients with *MAPT* and *PGRN* mutations.

Family	A		B		C		D		E	F	G
Patient	1	2	3	4	5	6	7	8	9	10	
Gene	<i>MAPT</i>										<i>PGRN</i>
Genotyping	Heterozygous										
Nucleotide change	c.853A > C	c.837T > G	c.837T > G	c.837T > G	c.837T > G	c.837T > G	c.837T > G	c.837T > G	c.796C > G	c.888T > C	c.1012_1013delGGinsC
Amino acid change	p.S285R	p.N279K	p.N279K	p.N279K	p.N279K	p.N279K	p.N279K	p.N279K	p.L266V	p.N296N	p.G338RfsX23
Exon	10	10	10	10	10	10	10	10	9	10	9
Mode of inheritance	<i>de novo</i>	AD	AD	AD	NA	AD	AD	AD	AD	AD	AD
Age at onset, years	46	42	44	46	41	42	43	37	44	44	59
Age at evaluation, years	47	47	45	50	44	44	45	38	49	61	
Age at death, years	49	54	56	alive	51	54	51	alive	alive	alive	
Sex	M	M	M	M	F	F	F	F	M	F	F
Clinical syndromes	PSP	PSP	PSP	PSP	PSP	PSP	PSP	bvFTD	PSP	PPA	
Clinical features											
Initial symptoms	P	P	P	P	P	P	P	dementia	P	aphasia	
Personality/behavior changes	–	+	–	–	–	–	–	+	+	–	
Mini mental state examination score	28/30	NA	NA	28/30	NA	NA	NA	0	24/30	29/30	
Hasegawa dementia scale-revised <sup>a</sup>	NA	18/30	NA	NA	21/30	28/30	30/30	0	21/30	29/30	
Nonfluent spontaneous speech	–	–	–	–	–	–	–	–	–	–	+
Apraxia of eyelid opening	–	+	+	+	+	+	+	–	–	–	
Abnormal eye movements											
Supranuclear gaze palsy	+	+	+	+	+	+	+	–	+	–	
Tonic upward ocular fixation	+	–	–	–	–	–	–	–	–	–	
Oscillopsia with CN	–	+	+	–	–	–	–	–	–	–	
Visual grasping	–	–	–	–	+	+	+	–	–	–	
Parkinsonism											
Bradykinesia	+	+	+	+	+	+	+	–	+	–	
Rigidity	–	+	+	+	+	+	+	–	+	–	
Tremor	–	+	+	–	–	–	–	–	–	–	
Postural instability	+	+	+	+	+	+	+	–	+	–	
Response to L-dopa	–	partial <sup>b</sup>	–	partial <sup>b</sup>	partial <sup>b</sup>	partial <sup>b</sup>	partial <sup>b</sup>	NA	+	NA	
Pyramidal sign	+	–	NA	–	+	+	+	+	+	+	
Features of motor neuron disease	–	–	–	–	–	–	–	–	–	–	
Reference					[19]	[19]	[19]				

AD = autosomal dominant.

P = parkinsonism; NA = not available.

CN = congenital nystagmus; PSP = progressive supranuclear palsy.

bvFTD = behavioral variant frontotemporal dementia; PPA = primary progressive aphasia.

<sup>a</sup> The Hasegawa dementia scale-revised is a brief dementia screening scale. The maximum score of the Hasegawa dementia scale-revised is 30 points. There was a significant difference in the mean score between the demented and non-demented subjects when the cut-off point was set at 20/21 [31].

<sup>b</sup> A partial response to L-dopa indicates that L-dopa was effective only in the early stages.

mutation in *PGRN*, p.G338RfsX23 (c.1012\_1013delGGinsC), was detected by direct sequencing and TOPO TA cloning sequencing (Supplementary Fig. 1). None of the 182 normal Japanese controls included in this study had the *PGRN* p.G338RfsX23 (c.1012\_1013delGGinsC) mutations. The age at disease onset of the patient with the heterozygous *PGRN* deletion/insertion was 59 years. Novel *PGRN* variants with unknown significance, p.R18Q and

p.N118del, are listed in Table 3. MLPA analysis showed no gene dosage abnormalities in *PGRN*.

### 3.2.2. A clinical presentation of a novel *PGRN* mutation

3.2.2.1. Patient 10 (*PGRN* p.G338RfsX23, c.1012\_1013delGGinsC). This patient, a 59-year-old woman, developed word-finding difficulties and underwent surgical clipping at age 54 for an unruptured

**Table 3**  
Novel variants with unknown significance.

Gene	Nucleotide change	Amino acid change	Exon	Amino acid conservation	Mean AAO (years)	Frequency		P value	Clinical diagnosis
						Patients N (%)	Controls N (%)		
<i>PGRN</i>	c.56G > A	p.R19Q	1	not conserved	66	1/69 (1.4)	0/186 (0)	0.605	PSP (n = 1)
<i>PGRN</i>	c.352_354delAAC	p.N118del	4	not conserved	53	3/69 (4.3)	3/272 (1.1)	0.187	bvFTD (n = 3)

AAO = age at onset.

PSP = progressive supranuclear palsy.

bvFTD = behavioral variant frontotemporal dementia.

aneurysm of the left middle cerebral artery. The patient's mother suffered from dementia, but the details of her disease were unknown. The patient substituted words for names of people and objects. Two years after the onset of symptoms, the patient became severely disfluent. However, she did not show any violent behavior, personality changes, or other behavioral abnormalities. The patient scored 29/30 on the MMSE. On the frontal assessment battery, she scored 13/18. The patient's time to complete the Trail Making Test (TMT) A was 70 s, and she could not finish the TMT B within five minutes. Her spontaneous speech production was characterized by slow and hesitant speech, frequently interrupted by long word-finding pauses. Her motor speech abilities were within the normal limits, and no apraxia of speech was noted. No parkinsonism was observed. The patient's clinical diagnosis was PPA with a family history of dementia.

### 3.3. Results of *C9orf72* analysis

We identified no patients with expanded hexanucleotide repeats in *C9orf72* in this study. In 75 patients, the average repeat number based on fluorescent fragment-length analysis was  $3.77 \pm 2.56$  (range 2–11 repeats). We have previously reported that an analysis of 197 Japanese healthy controls did not find any *C9orf72* mutation. The average repeat number was  $3.69 \pm 2.46$  (range 2–14 repeats) in the 197 controls [21].

## 4. Discussion

We identified five *MAPT* mutations, including a novel *de novo* mutation and a novel *PGRN* mutation, and we found no *C9orf72* mutations in our 75 patients. More mutations were found in *MAPT* than in the other two genes evaluated in this study. The infrequent observation of *PGRN* and *C9orf72* mutations might be partly due to the small number of FTLD patients included ( $n = 38$ ) because the majority of *PGRN* and *C9orf72* mutations have been described in patients with FTLD. In contrast to most other mutation screening studies, we performed MLPA analysis to ensure that exonic or larger deletions or multiplications of *MAPT* and *PGRN* would be identified. Therefore, our data also show that multiplications of *MAPT* and exonic or genomic deletions in *PGRN* are rare in Asian populations. Although mutations were detected in FTLD and PSP patients, we did not find any mutations in our CBS patients. A further larger study and investigation of the other genes are needed to clarify the genetic background of Japanese patients with CBS.

The *MAPT* p.S285R mutation, which we found in this study, is a novel *de novo* mutation. To the best of our knowledge, this report is the first description of an adult sporadic case of a *de novo* *MAPT* mutation associated with dementia and parkinsonism. All six patients (Patients 1, 2, 3, 5, 6, and 7) with PSP and the distinct eye movements described in the present study (such as tonic upward ocular fixation, oscillopsia with congenital nystagmus, and visual grasping) harbored *MAPT* mutations. Below, we discuss these abnormal eye movements, which are generally not observed in patients with sporadic PSP.

In Patient 1 (*MAPT* p.S285R), we observed tonic upward ocular fixation, which is a loss of downward saccades resembling an acquired ocular motor apraxia [22]. This condition is characterized by a loss of voluntary control of saccades and pursuit, whereas reflex movements—in particular, the vestibulo-ocular reflex—were preserved. Acquired ocular motor apraxia is usually the result of bilateral frontal or frontoparietal infarcts. Therefore, tonic upward ocular fixation due to a *MAPT* mutation might share “supranuclear” cerebral lesions in common with ocular motor apraxia. Brainstem functions, including the vestibulo-ocular reflex and Bell's phenomenon, were preserved in Patient 1.

In Patients 2 and 3 (*MAPT* p.N279K), pendular nystagmus was present since childhood and was suppressed with eyelid closure. These features are consistent with congenital nystagmus [23]. Most patients with congenital nystagmus do not complain of oscillopsia, despite having nearly continuous eye movement [23]. Notably, Patients 2 and 3 noticed oscillopsia when they developed parkinsonism. In these siblings, cerebral lesions caused solely by a *MAPT* mutation were unlikely to be the cause of their nystagmus; however, the co-existence of congenital nystagmus and the *MAPT* mutation might have caused the oscillopsia. This notion is supported in part because the patients had a sister who remained healthy — even in her late 60s — and did not complain of oscillopsia, despite having obvious pendular nystagmus (Fig. 1A). Thus, *MAPT* mutations might impair the visual-motion processing pathways that would normally suppress oscillopsia in patients with common congenital nystagmus. Visual grasping, which was first described by Ghika et al. [20], was observed in Patients 5, 6, and 7 (*MAPT* p.N279K) [19].

Although PSP is a rare manifestation of *MAPT* mutation [24], and the routine screening of sporadic PSP for mutations in *MAPT* is not recommended because of low yield [25], it is recommended that screening be considered for families in which there is an autosomal dominant history of a PSP syndrome, particularly when there are accompanying features suggestive of bvFTD [24]. The clinical difference from sporadic PSP might sometimes be difficult to detect, especially in patients without a family history [26–28]; however, an important case report indicated that an age at disease onset under 50 years combined with the absence of early falling may indicate a possible *MAPT* mutation in clinically diagnosed PSP, even in the absence of a positive family history [26]. Consistent with this observation, our eight *MAPT*-positive patients with PSP phenotype were younger than 50 years at disease onset (Table 2). We further suggest that it may be useful to test for *MAPT* mutations in early-onset PSP patients with the abnormal eye movements that are not typical of sporadic PSP. In fact, we identified the novel *de novo* mutation p.S285R in Patient 1 and p.N279K in Patient 5, who had no family history, after focusing on these clinical phenotypes.

To the best of our knowledge, the *PGRN* mutation has not been previously described in Asian populations [29]. We detected a novel *PGRN* mutation, p.G338RfsX23 (c.1012\_1013delGGinsC), and thus showed that *PGRN* mutations may exist in Asian populations. This mutation introduces a premature termination codon at the same site as the p.G333VfsX28 (c.998delG) mutation, which was reported previously, and produced a PPA phenotype in all of the affected individuals [30]. The PPA phenotype of p.G338RfsX23 (c.1012\_1013delGGinsC) in our study is remarkably similar to that of p.G333VfsX28 (c.998delG), especially in the manifestation of word-finding and object-naming difficulties and the lack of memory or personality changes during the first few years after symptom onset. We believe that the mutant RNA in both cases is most likely subjected to nonsense-mediated decay, similar to other *PGRN* mutations [2].

In summary, based on these findings, we recommend genetic testing for *MAPT* mutations not only in familial patients but also in sporadic patients, especially early-onset PSP patients with the abnormal eye movements that are generally not observed in sporadic PSP. Although *PGRN* and *C9orf72* mutations were rare in this study, we determined that the *PGRN* mutation does exist in Asian patients with FTLD (PPA). Based on the clinical information, screening for *MAPT*, *PGRN*, and *C9orf72* mutations should be further undertaken to improve the diagnosis of specific clinical entities of neurodegenerative disorders.

### Conflicts of interest

None.

## Acknowledgments


The authors thank all of the participants in this study. The authors also thank Dr. Mariely DeJesus-Hernandez for technical advice on the analysis of C9orf72 repeat expansion. This work was supported by the Strategic Research Foundation Grant-in-Aid Project for Private Universities, Grants-in-Aid for Scientific Research, Grant-in-Aid for Young Scientists, and Grant-in-Aid for Scientific Research on Innovative Areas from the Japanese Ministry of Education, Culture, Sports, Science and Technology, Grants-in-Aid from the Research Committee of CNS Degenerative Diseases and Muro Disease (Kii ALS/PDC), Grants-in-Aid from the Research Committee on CNS Degenerative Diseases and Perry Syndrome from the Ministry of Health, Labor and Welfare of Japan, Project Research Grants-in-Aid from Juntendo University School of Medicine, and CREST from the Japan Science and Technology Agency (JST).

## Appendix A. Supplementary data

Supplementary data related to this article can be found online at <http://dx.doi.org/10.1016/j.parkreldis.2012.06.019>.

## References

- [1] Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature* 1998;393:702–5.
- [2] Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature* 2006;442:916–9.
- [3] Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. *Nature* 2006;442:920–4.
- [4] DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* 2011;72:245–56.
- [5] Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-Linked ALS-FTD. *Neuron* 2011;72:257–68.
- [6] Boeve BF, Hutton M. Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN). *Arch Neurol* 2008;65:460–4.
- [7] Murray ME, DeJesus-Hernandez M, Rutherford NJ, Baker M, Duara R, Graff-Radford NR, et al. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. *Acta Neuropathol* 2011;122:673–90.
- [8] Lindquist S, Duno M, Batbayli M, Puschmann A, Braendgaard H, Mardosiene S, et al. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. *Clin Genetics* 2012 May 31 [Epub ahead of print].
- [9] Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. *Neurology* 1998;51:1546–54.
- [10] Mesulam MM. Slowly progressive aphasia without generalized dementia. *Ann Neurol* 1982;11:592–8.
- [11] Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. *Neurology* 1996;47:1–9.
- [12] Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. *Ann Neurol* 2003;54(Suppl. 5):S15–9.
- [13] Baker M, Kwok JB, Kucera S, Crook R, Farrer M, Houlden H, et al. Localization of frontotemporal dementia with parkinsonism in an Australian kindred to chromosome 17q21-22. *Ann Neurol* 1997;42:794–8.
- [14] Keyser RJ, Lombard D, Veikondis R, Carr J, Bardin S. Analysis of exon dosage using MLPA in South African Parkinson's disease patients. *Neurogenetics* 2010;11:305–12.
- [15] Varani L, Hasegawa M, Spillantini MG, Smith MJ, Murrell JR, Ghetti B, et al. Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17. *Proc Natl Acad Sci U S A* 1999;96:8229–34.
- [16] Kobayashi T, Ota S, Tanaka K, Ito Y, Hasegawa M, Umeda Y, et al. A novel L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology. *Ann Neurol* 2003;53:133–7.
- [17] Clark LN, Poorkaj P, Wszolek Z, Geschwind DH, Nasreddine ZS, Miller B, et al. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. *Proc Natl Acad Sci U S A* 1998;95:13103–7.
- [18] Spillantini MG, Yoshida H, Rizzini C, Lantos PL, Khan N, Rossor MN, et al. A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. *Ann Neurol* 2000;48:939–43.
- [19] Ogaki K, Motoi Y, Li Y, Tomiyama H, Shimizu N, Takanashi M, et al. Visual grasping in frontotemporal dementia and parkinsonism linked to chromosome 17 (microtubule-associated with protein tau): a comparison of N-Iso-propyl-p-[(123)I]-iodoamphetamine brain perfusion single photon emission computed tomography analysis with progressive supranuclear palsy. *Mov Disord* 2011;26:561–3.
- [20] Ghika J, Tennis M, Growdon J, Hoffman E, Johnson K. Environment-driven responses in progressive supranuclear palsy. *J Neurol Sci* 1995;130:104–11.
- [21] Ogaki K, Li Y, Atsuta N, Tomiyama H, Funayama M, Watanabe H, et al. Analysis of C9orf72 repeat expansion in 563 Japanese patients with ALS. *Neurobiol Aging* 2012 June 21 [Epub ahead of print].
- [22] Pierrot-Deseilligny C, Gautier JC, Loron P. Acquired ocular motor apraxia due to bilateral frontoparietal infarcts. *Ann Neurol* 1988;23:199–202.
- [23] Leigh RJZD. In: *The neurology of eye movements*. 4 ed. New York: Oxford University Press; 2006. p. 512–21, 638–45.
- [24] Rohrer JD, Paviour D, Vandrovцова J, Hodges J, de Silva R, Rossor MN. Novel L284R MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy syndrome. *Neurodegener Dis* 2011;8:149–52.
- [25] Williams DR, Pittman AM, Revesz T, Lees AJ, de Silva R. Genetic variation at the tau locus and clinical syndromes associated with progressive supranuclear palsy. *Mov Disord* 2007;22:895–7.
- [26] Morris HR, Osaki Y, Holton J, Lees AJ, Wood NW, Revesz T, et al. Tau exon 10 + 16 mutation FTDP-17 presenting clinically as sporadic young onset PSP. *Neurology* 2003;61:102–4.
- [27] Rossi G, Gasparoli E, Pasquali C, Di Fede G, Testa D, Albanese A, et al. Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene. *Ann Neurol* 2004;55:448.
- [28] Ros R, Thobois S, Streichenberger N, Kopp N, Sanchez MP, Perez M, et al. A new mutation of the tau gene, G303V, in early-onset familial progressive supranuclear palsy. *Arch Neurol* 2005;62:1444–50.
- [29] Kim HJ, Jeon BS, Yun JY, Seong MW, Park SS, Lee JY. Screening for MAPT and PGRN mutations in Korean patients with PSP/CBS/FTD. *Parkinsonism Relat Disord* 2010;16:305–6.
- [30] Mesulam MM. Primary progressive aphasia—a language-based dementia. *N Engl J Med* 2003;349:1535–42.
- [31] Imai Y, Hasegawa K. The revised hasegawa's dementia scale (HDS-R) – evaluation of its usefulness as a screening test for dementia. *J Hong Kong Coll Psychiatr* 1994;4:20–4.



## PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy

Kahori Shiba-Fukushima<sup>1</sup>, Yuzuru Imai<sup>2</sup>, Shigeharu Yoshida<sup>3</sup>, Yasushi Ishihama<sup>3</sup>, Tomoko Kanao<sup>4</sup>, Shigeto Sato<sup>1</sup> & Nobutaka Hattori<sup>1,2,4,5</sup>

<sup>1</sup>Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan, <sup>2</sup>Department of Neuroscience for Neurodegenerative Disorders, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan, <sup>3</sup>Department of Molecular and Cellular BioAnalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan, <sup>4</sup>Research Institute for Diseases of Old Age, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan, <sup>5</sup>CREST (Core Research for Evolutionary Science and Technology), JST, Saitama 332-0012, Japan.

Parkinson's disease genes *PINK1* and *parkin* encode kinase and ubiquitin ligase, respectively. The gene products PINK1 and Parkin are implicated in mitochondrial autophagy, or mitophagy. Upon the loss of mitochondrial membrane potential ( $\Delta\Psi_m$ ), cytosolic Parkin is recruited to the mitochondria by PINK1 through an uncharacterised mechanism – an initial step triggering sequential events in mitophagy. This study reports that Ser65 in the ubiquitin-like domain (Ubl) of Parkin is phosphorylated in a PINK1-dependent manner upon depolarisation of  $\Delta\Psi_m$ . The introduction of mutations at Ser65 suggests that phosphorylation of Ser65 is required not only for the efficient translocation of Parkin, but also for the degradation of mitochondrial proteins in mitophagy. Phosphorylation analysis of Parkin pathogenic mutants also suggests Ser65 phosphorylation is not sufficient for Parkin translocation. Our study partly uncovers the molecular mechanism underlying the PINK1-dependent mitochondrial translocation and activation of Parkin as an initial step of mitophagy.

Mutations of the *PINK1* gene cause selective degeneration of the midbrain dopaminergic neurons in autosomal recessive juvenile Parkinson's disease (PD)<sup>1</sup>. The *PINK1* gene encodes a serine/threonine kinase with a predicted mitochondrial target sequence and a putative transmembrane domain at the N-terminus<sup>2–5</sup>. Loss of the *PINK1* gene in *Drosophila* results in the degeneration of mitochondria in cells with high energy demands, such as muscle and sperm cells, which is suppressed by the introduction of the *parkin* gene, another gene responsible for autosomal recessive juvenile PD<sup>6–8</sup>. The gene product Parkin encodes a RING-finger type ubiquitin ligase (E3) with a Ubl domain at the N-terminus<sup>9–12</sup>.

A series of cell biological studies have provided strong evidence that there are important roles for PINK1 and Parkin in regulating mitochondrial homeostasis. PINK1 is constitutively proteolysed by the mitochondrial rhomboid protease, PARL, at the mitochondrial membrane of healthy mitochondria, resulting in processed forms of PINK1<sup>13–16</sup>. The processed PINK1 is rapidly degraded by the proteasome<sup>2,17</sup>. The reduction of  $\Delta\Psi_m$  leads to the accumulation and activation of PINK1 in the mitochondria<sup>17–19</sup> through a currently unresolved mechanism<sup>20</sup>. The accumulation of PINK1 recruits Parkin from the cytosol to the mitochondria with decreased membrane potential, which stimulates Parkin E3 activity, promoting mitochondrial degradation via an autophagic event known as mitophagy<sup>17,21–24</sup>. The recruitment of cytosolic Parkin to the mitochondria upon disruption of  $\Delta\Psi_m$  is believed to be the first step of mitophagy for the removal of damaged mitochondria. This recruitment is required for the kinase activity of PINK1<sup>17,21–25</sup>. Although two separate studies have proposed that Parkin is directly phosphorylated by PINK1<sup>26,27</sup>, others have failed to detect Parkin phosphorylation by PINK1<sup>21</sup>, suggesting that the kinase activity of PINK1 itself is relatively low. One reason biochemical analysis has been unable to obtain direct evidence is that recombinant human PINK1 purified from mammalian cultured cells or bacteria easily loses kinase activity, while insect PINK1 has significant autophosphorylation activity<sup>28,29</sup>.

SUBJECT AREAS:  
MITOPHAGY  
PHOSPHORYLATION  
CELL DEATH IN THE NERVOUS SYSTEM  
UBIQUITIN LIGASES

Received  
3 August 2012

Accepted  
5 December 2012

Published  
19 December 2012

Correspondence and requests for materials should be addressed to Y.I. (yzimai@juntendo.ac.jp) or N.H. (nhattori@juntendo.ac.jp)



Very recently, Kondapalli, C. *et al.* reported that PINK1 directly phosphorylates Parkin at Ser65 in the Ubl domain<sup>18</sup>. However, the extent and consequences of Parkin phosphorylation by PINK1 in mitochondrial regulation are still not fully understood.

To address this issue, we attempted to independently monitor and compare the phosphorylation status of Parkin in wild-type and *PINK1*-deficient cells, thereby excluding the possibility of phosphorylations by uncharacterised kinases other than PINK1<sup>30</sup>. Here, we also report that Parkin is demonstrably phosphorylated at Ser65 in a PINK1-dependent manner. Furthermore, we show that this phosphorylation event is implicated in the regulation of mitochondrial translocation of Parkin and the subsequent degradation of mitochondrial surface proteins during mitophagy.

## Results

**Parkin is phosphorylated upon depolarisation in  $\Delta\Psi_m$ .** We used [<sup>32</sup>P] orthophosphate to metabolically label mouse embryonic fibroblasts (MEFs) derived from *PINK1* deficient mice, in which HA-tagged Parkin together with FLAG-tagged wild-type or kinase-dead forms (triple mutant with K219A, D362A and D384A) of PINK1 were virally introduced (hereafter referred to as “PINK1-FLAG WT” or “KD/HA-Parkin/*PINK1*<sup>-/-</sup>” MEFs) and then induced Parkin-mediated mitophagy via treatment with the protonophore carbonyl cyanide *m*-chlorophenyl hydrazone (CCCP). As shown in Figure 1a, Parkin was specifically phosphorylated in CCCP-treated PINK1-FLAG WT/HA-Parkin/*PINK1*<sup>-/-</sup> MEFs, but not in PINK1-FLAG KD/HA-Parkin/*PINK1*<sup>-/-</sup> MEFs. Phos-tag Western blotting, in which phosphorylated proteins appear as slower migrating bands<sup>28</sup>, revealed that Parkin was phosphorylated within 10 min following CCCP treatment (Fig. 1b). Phosphorylation of Parkin reached its maximum level approximately 40 min after CCCP treatment and was sustained at least until 6 hr (Supplementary Fig. S1). Under these conditions, slower migrating bands of PINK1 also appeared, which very likely reflects the autophosphorylation of PINK1 when activated (Fig. 1b)<sup>18</sup>. The suppression of PINK1 accumulation by RNA interference suggested that  $\Delta\Psi_m$  depolarisation-dependent activation of PINK1 along with PINK1 accumulation is a key element for Parkin phosphorylation (Fig. 1c). Every PINK1 deletion and pathogenic mutant we tested failed to stimulate Parkin phosphorylation effectively, strongly suggesting that intact PINK1 is required for this action (Fig. 1d and e). Importantly, human fibroblasts from a patient with *PINK1*-linked parkinsonism also lacked the activity to phosphorylate Parkin (Fig. 1f). The phosphorylated Parkin disappeared within 30 min during the recovery of  $\Delta\Psi_m$  depolarisation by the removal of CCCP from the culture medium (Fig. 1g). Further analysis using phosphatase and proteasome inhibitors suggested that phosphorylated Parkin is at least partly degraded by proteasomal activity in the mitochondria (Supplementary Fig. S2).


**Phosphorylation of Ser65 in the Parkin Ubl domain primes the mitochondrial translocation of Parkin.** To determine which residue(s) of Parkin are phosphorylated, we immunopurified HA-tagged Parkin from PINK1-FLAG WT or KD/HA-Parkin/*PINK1*<sup>-/-</sup> MEFs treated with or without CCCP and performed mass spectrometric analysis for phospho-peptides (Supplementary Fig. S3). Although Phos-tag Western blotting of Parkin mainly detected a single band shift, which represents a single phospho-modification, the mass spectrometric analysis identified Ser9 or Ser10 and Ser65, Ser101 and Ser198 as phosphorylated residues of Parkin. Among these residues, only Ser65 phosphorylation increased (33-fold) in CCCP-treated PINK1-FLAG WT/HA-Parkin/*PINK1*<sup>-/-</sup> MEFs (Supplementary Fig. S3). Phos-tag Western blotting with mutant forms of Parkin, in which the identified phospho-serine residues are replaced with alanine, revealed that the band shift represents Ser65 phosphorylation (Fig. 2a). An *in vitro* kinase assay with recombinant insect PINK1, which has marked kinase activity<sup>28</sup>, strongly suggested that

PINK1 directly phosphorylates Parkin at Ser65 (Supplementary Fig. S4). The Ser65 residue lies in the Ubl domain and is highly conserved from human to *Drosophila* (Fig. 2b). We next examined whether phosphorylation of Ser65 is required for Parkin-mediated mitophagy. GFP-tagged Parkin WT, which was localised both in the cytoplasm and in the nuclei of mock (DMSO)-treated cells (0 hr, Fig. 2c and d), was translocated to the mitochondria and induced the perinuclear aggregation of mitochondria 2 hr after CCCP treatment, as previously reported (2 hr, Fig. 2c and d)<sup>17,23</sup>. Replacement of Ser65 with alanine (S65A) did not affect the subcellular localisation of Parkin in mock-treated cells when compared with that of GFP-Parkin WT (0 hr, Fig. 2c and d). However, GFP-Parkin S65A almost completely inhibited the mitochondrial translocation of Parkin and the perinuclear rearrangement of mitochondria 0.5 hr after CCCP treatment (0.5 hr, Fig. 2c and d) and showed delayed translocation in 2 hr (2 hr, Fig. 2c and d). The expression of a putative phosphomimetic Parkin S65E also showed a subcellular localisation similar to that of GFP-Parkin WT in both DMSO- and CCCP-treated cells (Fig. 2c). However, GFP-Parkin S65E exhibited a mild translocation defect, suggesting that S65E does not fully mimic the phosphorylated Ser65 (Fig. 2d).


**Parkin Ser65 phosphorylation is not sufficient for mitochondrial translocation upon depolarisation of  $\Delta\Psi_m$ .** As PINK1-mediated Ser65 phosphorylation appeared to be required for efficient translocation of Parkin, we next examined whether well-characterised pathogenic Parkin mutants were subjected to phosphorylation upon CCCP treatment. In this experiment, we used three kinds of Parkin mutants based on the previous and current studies (Supplementary Fig. S5)<sup>17,22,23</sup>. The first group, V15M, P37L, R42P and A46P, had intact or weakly impaired mitochondrial translocation activity. The second group, T415N and G430D, had mildly impaired translocation activity. The third group, K161N, K221N and T240R, almost completely lacked translocation activity (Fig. 3a). Surprisingly, all of the mutants possessed comparable phosphorylation efficiencies to those of WT (Fig. 3b). This result suggests that Ser65 phosphorylation is not sufficient for the mitochondrial translocation of Parkin.

Biochemical fractionation of endogenous Parkin from SH-SY5Y cells detected only the phosphorylated form of Parkin in the mitochondrial fraction upon CCCP treatment (Fig. 3c), which strongly suggests that phosphorylation of Parkin is required for mitochondrial translocation. There was a slight difference in the gel mobility of phosphorylated Parkin between the cytosolic and the mitochondrial fractions and between CCCP-treated periods of time. These differences very likely reflect differences in the complexity of the contents of each fraction rather than in the phosphorylation status of Parkin because a single shifted band appears in the mixed fractions (Mito + Cyto in Fig. 3c; CCCP 30 min + 60 min in Supplementary Fig. S6).


**Effect of Parkin Ser65 phosphorylation on the autophagic reaction.** We next examined whether Ser65 phosphorylation is required for the subsequent autophagic reaction, in which various ubiquitin-proteasome- and autophagy-related proteins are involved, including the 26S proteasome, p97/VCP, p62/SQSTM1, LC3, ATG5 and ATG7<sup>22,23,31–35</sup>. Parkin has been reported to be involved in the ubiquitin-proteasome-dependent degradation of a variety of mitochondrial outer membrane proteins, including Mitofusin1 (Mfn1)<sup>32</sup>, Mfn2<sup>32</sup>, Miro1<sup>36,37</sup>, Miro2<sup>37</sup>, VDAC1<sup>22</sup> and Tom20<sup>31</sup>. Degradation of Mfn1, VDAC1 and Tom20 at the mitochondrial outer membrane was observed in PINK1 WT/GFP-Parkin/*PINK1*<sup>-/-</sup> MEFs 1 to 4 hr after CCCP treatment (Fig. 4a). While GFP-Parkin harbouring S65A or S65E mutations was also capable of inducing Mfn1, VDAC1 and Tom20 degradation, the efficiency was impaired, especially in Mfn1 and VDAC1 (Fig. 4a). Long-term time course analysis revealed that in cells expressing Parkin with S65A or S65E mutations, Mfn1 and VDAC1 cannot be degraded effectively, and the mitochondrial outer membrane was likely more intact as indicated by the sustained



**Figure 1 | PINK1-dependent phosphorylation of Parkin *in vivo*.** (a) PINK1-FLAG WT or KD/HA-Parkin/*PINK1*<sup>-/-</sup> MEFs were labelled with [<sup>32</sup>P] orthophosphate and treated with 30 μM CCCP for 1.5 hr. Phosphorylated Parkin was detected by autoradiography (<sup>32</sup>P). Immunoprecipitated HA-Parkin was detected by Western blotting (WB) with anti-Parkin. (b) PINK1-FLAG WT or KD/HA-Parkin/*PINK1*<sup>-/-</sup> MEFs were treated with or without 30 μM CCCP for the indicated periods of time. Cell lysate was subsequently separated on a Phos-tag gel, followed by WB with anti-PINK1 or anti-Parkin antibodies (Phos-tag WB). Phosphorylated bands of Parkin and PINK1 were confirmed by their disappearance with lambda protein phosphatase (λPP) treatment. Mitochondrial Hsp60 was used as a loading control. (c) Suppression of endogenous PINK1 expression inhibits Parkin phosphorylation. HeLa cells stably expressing non-tagged Parkin were treated with the indicated concentrations of stealth siRNA duplex against PINK1 (Invitrogen) with or without 10 μM CCCP for 1 hr. Long- (LE) and short-exposure (SE) blot signals for PINK1 were shown. Actin was used as a loading control. (d) Truncated PINK1 mutants used in this study. Putative mitochondria-targeting sequence, 1–34 aa; transmembrane domain, 94–110 aa; kinase domain, 156–509 aa. (e) Full-length PINK1 is required for Parkin phosphorylation. *PINK1*<sup>-/-</sup> MEFs stably expressing non-tagged Parkin were transfected with various PINK1 constructs with C-terminal FLAG-tags. PINK1 expression was confirmed with anti-FLAG-HRP. (f) Human fibroblasts from a normal control and a *PARK6* case with a homozygous C388R mutation<sup>44</sup> were transfected with Parkin and were treated with or without 30 μM CCCP for 1 hr. (g) Cells treated with CCCP up to 60 min as in (b) were further incubated with fresh culture medium without CCCP for the indicated periods of time (Washout).



**Figure 2 | Ser65 in the Ubl domain of Parkin is phosphorylated upon depolarisation of  $\Delta\Psi_m$ .** (a) Phos-tag Western blotting detected phosphorylation of Ser65. HeLa cells were transiently transfected with Parkin WT and a series of alanine mutants for the candidate phospho-residues followed by treatment with or without 20  $\mu\text{M}$  CCCP for 1 hr. Cell lysates were analysed by Phos-tag Western blotting. An asterisk indicates degraded Parkin. (b) Alignment of the amino acid sequences surrounding Ser65 (marked by a black dot) from a variety of animal species. The numbers on the left correspond to the residue numbers of Parkin proteins. (c) Introduction of the S65A mutation delayed Parkin translocation to the depolarised mitochondria in PINK1 WT/GFP-Parkin/PINK1<sup>-/-</sup> MEFs. Cells retrovirally introduced with GFP-Parkin WT or its phospho-mutants (S65A and S65E) were treated with or without 30  $\mu\text{M}$  CCCP for the indicated periods of time. GFP-Parkin and mitochondria were visualised with anti-GFP (green) and anti-Tom20 (red), respectively. Parkin signals are also shown as monochrome images. Scale bar = 10  $\mu\text{m}$ . (d) Mitochondrial translocation efficiency of Parkin mutants. PINK1 WT/PINK1<sup>-/-</sup> MEFs stably expressing GFP-Parkin WT, S65A or S65E were treated as in (c). Cells expressing GFP-Parkin perfectly overlapped (Complete, examples are shown on the right), partially overlapped (Partial) or non-overlapped (No) with the Tom20 signal were counted. The data represent means  $\pm$  SE from three experiments ( $n = 99\text{--}143$  cells in each). \*\*  $p < 0.01$ , \*  $p < 0.05$  vs. WT at each time point.



**Figure 3 | Pathogenic mutants of Parkin are subjected to Ser65 phosphorylation.** (a) Diagram of Parkin protein illustrating the pathogenic mutants used in this study. The Ser65 residue in the Ub1 domain is shown as a yellow circle. RING, Ring-finger motif; IBR, in-between-Ring fingers domain. (b) Phos-tag Western blotting for Parkin and Western blotting for PINK1 were performed using Parkin WT and a series of pathogenic mutants as shown in Figure 2a. (c) Endogenous Parkin was also phosphorylated in SH-SY5Y cells after CCCP treatment. Post-nuclear cell lysates from SH-SY5Y cells treated with or without 10  $\mu$ M CCCP for 30 and 60 min were fractionated into mitochondria-rich (Mito) and cytosolic (Cyto) fractions. These two fractions and their combination (Mito + Cyto) were subjected to Phos-tag or normal Western blotting analyses. Endogenous PINK1 was fractionated in the Mito fraction, as previously reported<sup>45</sup>. Lactate dehydrogenase (LDH) and Tom20 were used as cytosolic and mitochondrial marker proteins, respectively. Asterisks: putative cleaved Parkin; dots: non-specific bands.

accumulation of PINK1 (Fig. 4b). The impaired degradation cannot be explained simply by the delayed translocation of Parkin mutants because both mutants completed the mitochondrial translocation by the 6 hr time-point (data not shown and see Fig. 4c). In contrast, the profiles of Parkin expression and autoubiquitination in Parkin S65A- or S65E-expressing cells were comparable with those of WT (Fig. 4b). We also examined whether Ser65 mutations affect the accumulation of proteasome (Fig. 4c) and p62 (Supplementary Fig. S7) at the mitochondria during mitophagy via the immunostaining of the proteasome subunit alpha type 7 ( $\alpha$ 7) and p62. However, there was no evidence that Ser65 mutations inhibit or delay the recruitment of proteasome and p62 to the mitochondria. Finally, we tested whether the Parkin Ub1 domain itself is indispensable for the mitochondrial


translocation and the substrate degradation (Supplementary Fig. S8). Interestingly, Parkin mutant lacking the Ub1 domain ( $\Delta$ Ub1) showed a mild delay in the mitochondrial translocation, slowed the mitochondrial reorganization to the perinuclear region (Supplementary Fig. S8b and c) and impaired the degradation of mitochondrial outer membrane proteins (Supplementary Fig. S8d). These results suggest that proper regulation of the Parkin Ub1 domain through the Ser65 phosphorylation is required not only for efficient translocation to mitochondria as an initial step of mitophagy, but also for the degradation of mitochondrial outer membrane proteins during mitophagy through an as yet unknown mechanism.

## Discussion

A series of *Drosophila* genetic and cell biological studies have clearly demonstrated that PINK1 is required for Parkin-mediated mitochondrial maintenance. The mitophagy of damaged mitochondria is a well-characterised event in which PINK1 and Parkin are involved. However, how PINK1 regulates Parkin is largely unclear. This study has shown that Ser65 in the Ub1 domain of endogenous Parkin is phosphorylated in an activated PINK1-dependent manner. In addition to mitochondrial accumulation of PINK1,  $\Delta\Psi$ m depolarisation-dependent PINK1 autophosphorylation has been reported to be an important element for PINK1 activation and Parkin recruitment<sup>19,29</sup>. Consistent with these observations, our investigation of PINK1 siRNA suggests that a lower level of PINK1 is able to phosphorylate Parkin after  $\Delta\Psi$ m depolarisation (Fig. 1c, compare lanes 1 and 4). Our domain analysis of PINK1 demonstrates that intact PINK1 is required for CCCP-dependent Parkin phosphorylation, and the lack of phosphorylation in fibroblasts from a *PARK6* patient implies relevance to the pathogenesis of PD.

The biological significance of this phosphorylation event is suggested by the fact that replacement of Ser65 with alanine or glutamic acid impairs the mitochondrial translocation of Parkin and/or the subsequent mitophagy process. Our observation that maximal phosphorylation of Parkin occurs within 1 hr of CCCP treatment supports the idea that Ser65 phosphorylation is required for the early step of Parkin translocation. In contrast, PINK1 accumulation appears to last at least 6 hr (Fig. 4c and Supplementary Fig. S1b). The difference in time course between PINK1 accumulation and Parkin phosphorylation could be explained by the observation that phosphorylated Parkin is degraded by proteasomal activity. The biochemical evidence that only the phosphorylated form of endogenous Parkin is present in the mitochondrial fraction also implies that Parkin phosphorylation is an essential event for its mitochondrial translocation and subsequent activation (Fig. 3c and Supplementary Fig. S6). Overexpression of PINK1 and Parkin itself leads to mitochondrial translocation, which suggests that excessive amounts of PINK1 and Parkin do not faithfully reflect endogenous reactions. Our study using *PINK1*<sup>-/-</sup> MEFs stably co-expressing PINK1 and GFP-Parkin might also be saddled with such a problem. We believe that the endogenous observation in which phosphorylated Parkin is accumulated in mitochondria is a more reliable proposal as a molecular model. The delay of exogenous GFP-Parkin S65A in the mitochondrial translocation would indicate that modification of Ser65 is important for Parkin translocation at least. At the same time, another important finding is that pathogenic mutants that lose their translocation activity are also phosphorylated (Fig. 3b), raising the possibility that phosphorylation of Parkin at Ser65 is insufficient for translocation. Thus, Ser65 phosphorylation likely leads to other events in mitochondrial translocation, such as the association or dissociation of protein(s) involved in the mitochondrial translocation of Parkin or the modification of Parkin itself for activation at a different site(s).

Both the S65A and S65E Parkin mutants cannot undergo efficient mitophagy, as indicated by the incomplete degradation of



**Figure 4 | Ser65 phosphorylation affects the subsequent autophagy reaction.** (a) CCCP-dependent degradation of mitochondrial outer membrane proteins in *PINK1* WT/*PINK1*<sup>-/-</sup> MEFs expressing WT or mutant forms of GFP-Parkin. Mfn1, VDAC1 and Tom20 were used as markers of mitochondrial outer membrane proteins. Actin: a loading control. Dots: ubiquitinated Mfn1. (b) Long-term time-course analysis of CCCP-dependent mitochondrial protein degradation. The degradation of outer membrane proteins was impaired in cells expressing GFP-Parkin S65A or S65E mutations. Hsp60 was used as a marker of mitochondrial matrix proteins. (c) S65A and S65E mutations do not affect proteasome recruitment to the mitochondria during mitophagy. *PINK1* WT/*PINK1*<sup>-/-</sup> MEFs expressing WT or mutant forms of GFP-Parkin (green) were treated with 30 μM CCCP for 3 or 6 hr. Cells were stained with anti-proteasome subunit alpha type 7 (α7, red). α7-immunoreactivity was enriched in the nuclei of all three cell genotypes under normal conditions, as displayed in the representative image of S65E (CCCP 0 hr), and overlapped with the aggregated mitochondria (arrowheads) 6 hr after CCCP treatment irrespective of genotype. Similar results were obtained 3 hr after CCCP treatment. Scale bar = 10 μm. (d) Model for Parkin translocation and activation. The Parkin Ubl domain masks C-terminal RING-IBR-RING (RBR) domains for E3 activity<sup>46</sup>. A Parkin phosphorylation event at Ser65 (P), combined with unknown factor(s) (?), stimulates the mitochondrial translocation of Parkin, releasing the RBR domains from autoinhibition by the Ubl domain.

the mitochondrial outer membrane proteins. Because inhibition of the degradation of the mitochondrial outer membrane proteins by proteasome inhibitors is reported to block mitophagy<sup>32,35</sup>, it may be that the modification of Parkin Ser65 has a greater than expected impact on the mitophagy process. Although our study does not demonstrate that the S65E mutant behaves exactly like the phosphorylated form of Parkin, the S65E mutant does

translocate to the mitochondria in a similar way to WT, although with slightly impaired efficiency, suggesting that S65E has at least some properties that are similar to phosphorylated Parkin. Currently, it is unknown why S65E also inhibits the later processes of mitophagy. One possible explanation is that rapid degradation of phosphorylated Parkin is required for the proper progression of mitophagy, and S65E may not be degraded effectively. However,

there is no evidence that S65E is more stable than WT, as shown in Figure 4c.

Very recently, Kondapalli *et al.* proposed a model to explain the biological significance of Ser65 phosphorylation, in which Ser65 phosphorylation relieves autoinhibition of Parkin E3 activity by the Ubl domain<sup>18</sup>. This model may explain the depolarised  $\Delta\Psi_m$ -dependent activation of Parkin. However, our data indicated that the Parkin S65A mutant is also autoubiquitinated (Fig. 4b) and that the  $\Delta Ubl$  mutant showed mild translocation defect and impaired substrate degradation (Supplementary Fig. S8). Moreover, if this is the case, the E3 activity of Parkin pathogenic mutants lacking mitochondrial translocational activity but harbouring intact E3 activity *in vitro* (such as K161N and K211N, which are subjected to the Ser65 phosphorylation) should be activated in the cytosol<sup>38</sup>. However, our previous data indicate that K161N and K211N are not activated by CCCP treatment<sup>23</sup>. Thus, it is conceivable that another step is required for depolarised  $\Delta\Psi_m$ -dependent activation of Parkin E3. In addition, the Ubl domain might not only autoinhibit its E3 activity but also contribute to the mitochondrial translocation and the substrate degradation through an as yet unknown mechanism. We believe that an appropriate way to estimate Parkin E3 activity in the context of mitophagy is to evaluate the ubiquitination and degradation of substrates in cells with depolarised  $\Delta\Psi_m$ . Mfn1 is a well-characterised direct substrate of Parkin<sup>32</sup>, and Parkin-dependent poly-ubiquitination modification of Mfn1 can be detected by Western blotting upon  $\Delta\Psi_m$  depolarisation<sup>32,39,40</sup>. Parkin S65A and S65E appear to ubiquitinate Mfn1, as poly-ubiquitinated forms of Mfn1 were observed (Fig. 4b). However, they cannot degrade it effectively, which suggests that the process of substrate degradation is also impaired in these mutants.

Kondapalli *et al.* have also shown that *T. castaneum* PINK1 (TcPINK1) directly phosphorylates human Parkin at Ser65<sup>18</sup>. We confirmed their finding using recombinant TcPINK1 produced from the same construct (Supplementary Fig. S4). The replacement of MBP-Parkin Ser65 with alanine completely abolished PINK1-mediated phosphorylation, indicating that Ser65 is the sole phosphorylation site *in vitro*. However, experiments in cultured cells showed that the replacement of Ser9, Ser10, Ser101 and Ser198 with alanine affects the Ser65 phosphorylation efficiency (Ser9, ~35% reduction; Ser10, ~76% reduction; Ser101, ~65% reduction; Ser198, ~92% reduction) (Fig. 2a). These residues might be priming phosphorylation sites for Ser65 phosphorylation.

Because PINK1 is believed to be activated in the mitochondria, a topological inconsistency arises from our cell-based data that cytosolic Parkin lacking the mitochondrial translocation activity is phosphorylated. Therefore, it is possible that PINK1 indirectly regulates Parkin phosphorylation. One possible explanation for this is the presence of another cytosolic kinase(s) regulated by PINK1 (Fig. 4d). Alternatively, because mitochondria are a dynamic organelle, cytosolic Parkin adjacent to the moving and fragmented mitochondria with depolarised  $\Delta\Psi_m$  might be phosphorylated incidentally. The issue as to whether or not PINK1 directly phosphorylates Parkin in cells remains to be solved.

In conclusion, this study has suggested that PINK1-dependent Parkin phosphorylation at Ser65 accelerates the mitochondrial translocation of Parkin and showed that the introduction of mutations at this site also affects subsequent mitophagy processes. Concurrently, our data provide the possibility that there is an elaborate multi-step mechanism for the mitochondrial translocation of Parkin upon the loss of  $\Delta\Psi_m$  (Fig. 4d), the clarification of which awaits further study.

## Methods

**Antibodies, plasmids and cell lines.** Antibodies used in Western blot analysis were as follows: anti-Parkin (1 : 1,000 and 1 : 5,000 dilution for endogenous and exogenous Parkin, respectively; Cell Signaling Technology, clone PRK8), anti-PINK1 (1 : 1,000 dilution; Novus, BC100-494 or 1 : 1,000 dilution; Cell Signaling Technology, clone D8G3), anti-Mfn1 (1 : 1,000 dilution; Abnova, clone 3C9), anti-VDAC1 (1 : 1,000

dilution; Abcam, Ab15895), anti-Tom20 (1 : 500 dilution; Santa Cruz Biotechnology, FL-145), anti-FLAG-HRP (1 : 2,000 dilution; Sigma-Aldrich, clone M2), anti-GFP (1 : 5,000 dilution; Abcam, ab290), anti-Actin (1 : 10,000 dilution; Millipore, MAb1501), anti-LDH (1 : 1,000 dilution; Abcam, ab7639-1), anti-phospho-GSK3 $\beta$  (1 : 1,000 dilution; Cell Signaling Technology, clone 5B3), anti-GSK3 $\beta$  (1 : 1,000 dilution; Cell Signaling Technology, clone 27C10), and anti-Hsp60 (1 : 10,000 dilution; BD Biosciences, clone 24/Hsp60). Antibodies used in immunocytochemistry were as follows: FITC-conjugated anti-GFP (1 : 1,000 dilution; Abcam, ab6662), anti-Tom20 (1 : 1,000 dilution; Santa Cruz Biotechnology, FL-145), anti-Myc (1 : 500 dilution; Millipore, clone 4A6), anti-p62 (1 : 500 dilution; Progen Biotechnik, GP62-C), anti-Parkin (1 : 1,000 dilution; Cell Signaling Technology, clone PRK8) and anti-proteasome  $\alpha 7$  (1 : 250; a kind gift of Dr S. Murata at the University of Tokyo). cDNAs for human Parkin, PINK1 and its pathogenic and engineered mutants are as described in previous studies<sup>23,41</sup>. Parkin phospho-mutants were generated by PCR-based mutagenesis followed by sequencing confirmation of the entire gene. PINK1<sup>-/-</sup> MEFs, cultured as previously described<sup>23</sup>, were retrovirally transfected with pMXs-puro harbouring non-tagged PINK1, PINK1-FLAG, non-tagged Parkin, HA-Parkin, GFP-Parkin and related cDNA; transfected cells were then selected with 1  $\mu$ g/ml puromycin. HeLa cells maintained at 37°C in a 5% CO<sub>2</sub> atmosphere in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FCS and 1x non-essential amino acids (GIBCO) were retrovirally transfected with pMXs-puro harbouring non-tagged Parkin along with pcDNA3Hyg-mSlc7a1-VSVG and pcDNA3Hyg-mSlc7a1-FLAG (a kind gift of Dr N. Fujita at UCSD). Stable cell lines were selected with 1  $\mu$ g/ml puromycin and cloned. Transient transfections of cultured cells were performed using Lipofectamine 2000 (Invitrogen) for plasmids and Lipofectamine RNAiMAX (Invitrogen) for stealth siRNA duplexes (Invitrogen), which were used according to the manufacturer's instructions.

**Tissue culture.** Skin biopsies were obtained from a PARK6 case and a control without mutations in any known PD genes. The study was approved by the ethics committee of Juntendo University, and all participants gave written, informed consent. Dermal primary fibroblasts established from biopsies were cultured in high glucose DMEM supplemented with 10% foetal bovine serum, 1x non-essential amino acids, 1 mM sodium pyruvate (GIBCO), 100  $\mu$ M 2-mercaptoethanol, and 1% penicillin-streptomycin at 37°C in a 5% CO<sub>2</sub> atmosphere.

**Mapping of Parkin phosphorylation sites.** PINK1<sup>-/-</sup> MEFs (6.0  $\times$  10<sup>7</sup>) expressing HA-Parkin and PINK1-FLAG were treated with or without 30  $\mu$ M CCCP for 30 min. HA-Parkin (~500 ng in each) immunopurified with anti-HA-conjugated agarose beads was eluted with 8 M urea buffered with 50 mM Tris-HCl at pH 9.0. Samples from two independent experiments were digested with trypsin or chymotrypsin and analysed by nano-scale liquid chromatography-tandem mass spectrometry (Dionex Ultimate3000 RSLCnano and ABSciex TripleTOF 5600) followed by MASCOT searching and Mass Navigator/PhosPepAnalyzer processing for identification and label-free quantitation, respectively<sup>42</sup>. Determination of phosphosite localisation was performed based on the presence of site-determining ions<sup>43</sup>.

**Phosphorylation assay and mitochondrial fractionation.** PINK1<sup>-/-</sup> MEFs harbouring HA-Parkin along with wild-type or a kinase-dead form of PINK1-FLAG were metabolically labelled with 175  $\mu$ Ci/ml of [<sup>32</sup>P] orthophosphate in phosphate-free DMEM (GIBCO) with 10% FBS at 37°C for 3 hr. The medium was then replaced with fresh DMEM containing 10% FBS. Cells were treated with CCCP for 1.5 hr and were lysed on ice with lysis buffer containing 0.2% NP-40, 50 mM Tris (pH 7.4), 150 mM NaCl and 10% glycerol supplemented with protease inhibitor (Roche Diagnostics) and phosphatase inhibitor (Pierce) cocktails, and HA-Parkin and PINK1-FLAG were immunoprecipitated with anti-HA (Wako Pure Chemical, clone 4B2)- or anti-FLAG (Sigma-Aldrich, clone M2)-conjugated agarose beads. Immunoprecipitates were separated by SDS-PAGE and transferred onto a PVDF membrane. Autoradiography and Western blotting were performed to visualise proteins. Phos-tag Western blotting was performed as previously described<sup>28</sup>. Briefly, phospho-Parkin and phospho-PINK1 were separated on 8% gels containing 50  $\mu$ M Phos-tag. Mitochondrial and cytosolic fractionations were performed as previously described, with some modifications<sup>20</sup>. The cytosolic fractions were further clarified by a second centrifugation at 105,000 g for 60 min to remove residual organelle membranes.

**Immunocytochemical analysis.** Cells plated on 3.5 mm glass-bottom dishes (MatTek) were fixed with 4% paraformaldehyde in PBS and permeabilised with 50  $\mu$ g/ml digitonin for anti-Tom20 and anti-p62 staining or with 0.1% NP-40 for anti- $\alpha 7$  staining in PBS. Cells were stained with anti-Tom20 or anti- $\alpha 7$  antibodies in combination with FITC-conjugated anti-GFP antibody and were counterstained with DAPI for nuclei. Cells were imaged using laser-scanning microscope systems (TCS-SP5, Leica or LSM510 META, Carl Zeiss).

**Statistical analysis.** A one-way repeated measures ANOVA was used to determine significant differences between multiple groups unless otherwise indicated. If a significant result was achieved ( $p < 0.05$ ), the means of the control and the specific test group were analysed using the Tukey-Kramer test.

1. Valente, E. M. *et al.* Hereditary early-onset Parkinson's disease caused by mutations in PINK1. *Science* **304**, 1158–1160 (2004).

2. Takatori, S., Ito, G. & Iwatsubo, T. Cytoplasmic localization and proteasomal degradation of N-terminally cleaved form of PINK1. *Neurosci Lett* **430**, 13–17 (2008).
3. Beilina, A. *et al.* Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. *Proc Natl Acad Sci U S A* **102**, 5703–5708 (2005).
4. Silvestri, L. *et al.* Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. *Hum Mol Genet* **14**, 3477–3492 (2005).
5. Sim, C. H. *et al.* C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. *Hum Mol Genet* **15**, 3251–3262 (2006).
6. Clark, I. E. *et al.* Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. *Nature* **441**, 1162–1166 (2006).
7. Park, J. *et al.* Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. *Nature* **441**, 1157–1161 (2006).
8. Yang, Y. *et al.* Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. *Proc Natl Acad Sci U S A* **103**, 10793–10798 (2006).
9. Kitada, T. *et al.* Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature* **392**, 605–608 (1998).
10. Imai, Y., Soda, M. & Takahashi, R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. *J Biol Chem* **275**, 35661–35664 (2000).
11. Shimura, H. *et al.* Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. *Nat Genet* **25**, 302–305 (2000).
12. Zhang, Y. *et al.* Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. *Proc Natl Acad Sci U S A* **97**, 13354–13359 (2000).
13. Deas, E. *et al.* PINK1 cleavage at position A103 by the mitochondrial protease PARL. *Hum Mol Genet* **20**, 867–879 (2011).
14. Jin, S. M. *et al.* Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. *J Cell Biol* **191**, 933–942 (2010).
15. Meissner, C., Lorenz, H., Weihofen, A., Selkoe, D. J. & Lemberg, M. K. The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. *J Neurochem* **117**, 856–867 (2011).
16. Whitworth, A. J. *et al.* Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and Parkin. *Dis Model Mech* **1**, 168–174; discussion 173 (2008).
17. Narendra, D. P. *et al.* PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. *PLoS Biol* **8**, e1000298 (2010).
18. Kondapalli, C. *et al.* PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. *Open Biol* **2**, 120080 (2012).
19. Okatsu, K. *et al.* PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria. *Nat Commun* **3**, 1016 (2012).
20. Lazarou, M., Jin, S. M., Kane, L. A. & Youle, R. J. Role of PINK1 binding to the TOM complex and alternate intracellular membranes in recruitment and activation of the E3 ligase Parkin. *Dev Cell* **22**, 320–333 (2012).
21. Vives-Bauza, C. *et al.* PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. *Proc Natl Acad Sci U S A* **107**, 378–383 (2010).
22. Geisler, S. *et al.* PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. *Nat Cell Biol* **12**, 119–131 (2010).
23. Matsuda, N. *et al.* PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. *J Cell Biol* **189**, 211–221 (2010).
24. Kawajiri, S. *et al.* PINK1 is recruited to mitochondria with parkin and associates with LC3 in mitophagy. *FEBS Lett* **584**, 1073–1079 (2010).
25. Ziviani, E., Tao, R. N. & Whitworth, A. J. Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. *Proc Natl Acad Sci U S A* **107**, 5018–5023 (2010).
26. Sha, D., Chin, L. S. & Li, L. Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling. *Hum Mol Genet* **19**, 352–363 (2010).
27. Kim, Y. *et al.* PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. *Biochem Biophys Res Commun* **377**, 975–980 (2008).
28. Imai, Y. *et al.* The loss of PGAM5 suppresses the mitochondrial degeneration caused by inactivation of PINK1 in Drosophila. *PLoS Genet* **6**, e1001229 (2010).
29. Woodroof, H. I. *et al.* Discovery of catalytically active orthologues of the Parkinson's disease kinase PINK1: analysis of substrate specificity and impact of mutations. *Open Biol* **1**, 110012 (2011).
30. Yamamoto, A. *et al.* Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity. *J Biol Chem* **280**, 3390–3399 (2005).
31. Narendra, D., Tanaka, A., Suen, D. F. & Youle, R. J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. *J Cell Biol* **183**, 795–803 (2008).
32. Tanaka, A. *et al.* Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. *J Cell Biol* **191**, 1367–1380 (2010).
33. Okatsu, K. *et al.* p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria. *Genes Cells* **15**, 887–900 (2010).
34. Narendra, D., Kane, L. A., Hauser, D. N., Fearnley, I. M. & Youle, R. J. p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. *Autophagy* **6**, 1090–1106 (2010).
35. Chan, N. C. *et al.* Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. *Hum Mol Genet* **20**, 1726–1737 (2011).
36. Wang, X. *et al.* PINK1 and Parkin Target Miro for Phosphorylation and Degradation to Arrest Mitochondrial Motility. *Cell* **147**, 893–906 (2011).
37. Liu, S. *et al.* Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. *PLoS Genet* **8**, e1002537 (2012).
38. Matsuda, N. *et al.* Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro. *J Biol Chem* **281**, 3204–3209 (2006).
39. Gegg, M. E. *et al.* Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. *Hum Mol Genet* **19**, 4861–4870 (2010).
40. Rakovic, A. *et al.* Mutations in PINK1 and Parkin impair ubiquitination of Mitofusins in human fibroblasts. *PLoS One* **6**, e16746 (2011).
41. Shiba, K. *et al.* Parkin stabilizes PINK1 through direct interaction. *Biochem Biophys Res Commun* **383**, 331–335 (2009).
42. Iwasaki, M., Sugiyama, N., Tanaka, N. & Ishihama, Y. Human proteome analysis by using reversed phase monolithic silica capillary columns with enhanced sensitivity. *J Chromatogr A* **1228**, 292–297 (2012).
43. Beausoleil, S. A., Villen, J., Gerber, S. A., Rush, J. & Gygi, S. P. A probability-based approach for high-throughput protein phosphorylation analysis and site localization. *Nat Biotechnol* **24**, 1285–1292 (2006).
44. Li, Y. *et al.* Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism. *Neurology* **64**, 1955–1957 (2005).
45. Zhou, C. *et al.* The kinase domain of mitochondrial PINK1 faces the cytoplasm. *Proc Natl Acad Sci U S A* **105**, 12022–12027 (2008).
46. Chaugule, V. K. *et al.* Autoregulation of Parkin activity through its ubiquitin-like domain. *EMBO J* **30**, 2853–2867 (2011).

## Acknowledgements

We thank: Drs K. Tanaka, N. Matsuda, K. Okatsu, T. Kitamura, S. Murata, N. Fujita, N. Furuya, M.M.K. Muqit and R.J. Youle for their generous supply of materials; T. Hasegawa and Y. Imaizumi for the preparation of human fibroblasts; and T. Imura for her technical help. This study was supported by the Naito Foundation, the Novartis Foundation, the Grant-in-Aid for Young Scientists (B) from MEXT in Japan (SK-F, YI), the CREST program of JST (NH) and Grant-in-Aid for Scientific Research on Innovative Areas (NH).

## Author contributions

K.S., Y. Imai and N.H. designed the research; K.S., Y. Imai, S.Y., T.K. and Y. Ishihama performed the experiments; S.S. contributed new reagents/analytic tools; K.S. and Y. Imai analysed the data; and Y. Imai and N.H. wrote the paper. K.S. and Y. Imai contributed equally to this work.

## Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

Competing financial interests: The authors declare no competing financial interests.

License: This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>

How to cite this article: Shiba-Fukushima, K. *et al.* PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy. *Sci. Rep.* **2**, 1002; DOI:10.1038/srep01002 (2012).

## VPS35 Mutation in Japanese Patients with Typical Parkinson's Disease

Maya Ando, MD,<sup>1</sup> Manabu Funayama, PhD,<sup>1,2\*</sup> Yuanzhe Li, MD, PhD,<sup>2</sup> Kenichi Kashihara, MD, PhD,<sup>3</sup> Yoshitake Murakami, MD,<sup>4</sup> Nobutaka Ishizu, MD,<sup>5</sup> Chizuko Toyoda, MD,<sup>6</sup> Katsuhiko Noguchi, MD,<sup>7</sup> Takashi Hashimoto, MD,<sup>8</sup> Naoki Nakano, MD,<sup>9</sup> Ryogen Sasaki, MD, PhD,<sup>10</sup> Yasumasa Kokubo, MD, PhD,<sup>10</sup> Shigeki Kuzuhara, MD, PhD,<sup>11</sup> Kotaro Ogaki, MD,<sup>1</sup> Chikara Yamashita, MD,<sup>1</sup> Hiroyo Yoshino, PhD,<sup>2</sup> Taku Hatano, MD, PhD,<sup>1</sup> Hiroyuki Tomiyama, MD, PhD,<sup>1,12</sup> and Nobutaka Hattori, MD, PhD<sup>1,2,12\*</sup>

<sup>1</sup>Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan

<sup>2</sup>Research Institute for Diseases of Old Age, Graduate School of Medicine, Juntendo University, Tokyo, Japan

<sup>3</sup>Department of Neurology, Okayama Kyokuto Hospital, Okayama, Japan

<sup>4</sup>Department of Neurology, Saiseikai Kurihashi Hospital, Saitama, Japan

<sup>5</sup>Department of Neurology, Saitama National Hospital, Saitama, Japan

<sup>6</sup>Department of Neurology, Jikei Daisan Hospital, Tokyo, Japan

<sup>7</sup>Department of Neurology, Kakio Kinen Hospital, Tokyo, Japan

<sup>8</sup>Hashimoto Clinic, Osaka, Japan

<sup>9</sup>Department of Neurosurgery, Kinki University Hospital, Osaka, Japan

<sup>10</sup>Department of Neurology, Mie University Graduate School of Medicine, Tsu, Mie, Japan

<sup>11</sup>Department of Medical Welfare, Faculty of Health Science, Suzuka University of Medical Science, Suzuka, Mie, Japan

<sup>12</sup>Department of Neuroscience for Neurodegenerative Disorders, Juntendo University School of Medicine, Tokyo, Japan

**ABSTRACT:** Vacuolar protein sorting 35 (*VPS35*) was recently reported to be a pathogenic gene for late-onset autosomal dominant Parkinson's disease (PD), using exome sequencing. To date, *VPS35* mutations have been detected only in whites with PD. The aim of the present study was to determine the incidence and clinical features of Asian PD patients with *VPS35* mutations. We screened 7 reported nonsynonymous missense variants of *VPS35*, including p.D620N, known as potentially disease-associated variants of PD, in 300 Japanese index patients with autosomal dominant PD and 433 patients with sporadic PD (SPD) by direct sequencing or high-resolution melting (HRM) analysis. In addition, we screened 579 controls for the p.D620N mutation by HRM analysis. The p.D620N mutation was detected in 3 patients with autosomal dominant PD (1.0%), in 1 patient with SPD (0.23%), and in no con-

trols. None of the other reported variants of *VPS35* were detected. Haplotype analysis suggested at least 3 independent founders for Japanese patients with p.D620N mutation. Patients with the *VPS35* mutation showed typical tremor-predominant PD. We report Asian PD patients with the *VPS35* mutation. Although *VPS35* mutations are uncommon in PD, the frequency of such mutation is relatively higher in Japanese than reported in other populations. In *VPS35*, p.D620N substitution may be a mutational hot spot across different ethnic populations. Based on the clinical features, *VPS35* should be analyzed in patients with PD, especially autosomal dominant PD or tremor-predominant PD. © 2012 Movement Disorder Society

**Key Words:** Parkinson's disease; *VPS35*; autosomal dominant; hotspot; mutation.

\*Correspondence to: Dr. Manabu Funayama or Prof. Dr. Nobutaka Hattori, Research Institute for Diseases of Old Age, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan; funayama@juntendo.ac.jp or nhattori@juntendo.ac.jp

**Funding agencies:** This work was supported by Strategic Research Foundation Grant-in-Aid Project for Private Universities, Grants-in-Aid for Scientific Research (80218510 [to N.H.] and 21591098 [to H.T.]), Grant-in-Aid for Young Scientists (22790829 [to M.F.] and 23791003 [to Y.L.]), Grant-in-Aid for Scientific Research on Innovative Areas (23111003 [to N.H.] and 23129506 [to M.F.]) from the Japanese Ministry of Education, Culture, Sports, Science and Technology, and Grant-in-Aid from the Research Committee on Muro Disease (Kii ALS/PDC; 21210301 [to Y.K.]), the Ministry of Health, Labor, and Welfare, and JST, CREST.

**Relevant conflicts of interest/financial disclosures:** Nothing to report.

Full financial disclosures and author roles may be found in the online version of this article.

Received: 5 March 2012; Revised: 11 July 2012; Accepted: 17 July 2012

Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.25145



Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive motor disturbances manifested by tremor, rigidity, akinesia, and postural instability. Neuropathologically, PD is characterized by selective loss of dopaminergic neurons in the substantia nigra and the presence of cytosolic inclusions called Lewy bodies (LBs) in the remaining neurons. The pathogenesis of PD is multifactorial, including genetic-environmental interaction. PD is a common disease in the elderly, with an incidence of about 1%–2% in individuals older than 60 years.<sup>1</sup> Among PD patients, approximately 5%–10% have a positive family history of PD,<sup>2</sup> and among these, the Mendelian forms of PD can contribute to the elucidation of the molecular pathways that lead to the degeneration and death of dopaminergic neurons.

Mutations in the vacuolar protein sorting 35 (*VPS35*) gene have recently been identified in families with autosomal dominant late-onset PD (MIM 601501).<sup>3,4</sup> Patients with *VPS35* mutations present with tremor-predominant dopa-responsive parkinsonism.<sup>3,4</sup> *VPS35*, a key component of the retromer cargo-recognition complex, is thought to associate with sorting cargos into the tubular endosomal network for retrieval to the trans-Golgi network.<sup>5</sup> Therefore, pathogenic mutations of *VPS35* may cause disruption of the retrograde transport system and contribute to dopaminergic neuronal cell death in PD. One missense mutation has been reported to be pathogenic for PD.<sup>3,4</sup> Mutation of c.1858G>A (p.D620N) was identified in 3 Austrian families and 1 family each in Switzerland, the United States, Tunisia, and the United Kingdom, as well as 1 family and 1 patient with sporadic PD (SPD) among Yemenite Jews from Israel.<sup>3,4,6</sup> In addition, several variants, such as p.M57I, p.I241M, p.P316S, and p.R524W, have been reported in Europe and the United States as potentially pathogenic for PD.<sup>3,4</sup>

Although multipopulation screenings for *VPS35* mutations were performed in recent reports, there is still no report of PD patients with *VPS35* mutations of Asian ancestry.<sup>3,4,6–8</sup> In the present study, we screened Japanese patients with autosomal-dominant PD (ADPD), Japanese patients with SPD, and control subjects for mutations of *VPS35*, with a special focus on 7 reported nonsynonymous variants that were found in patients with PD, including the p.D620N. Here, we report 3 families and 1 SPD patient with the p.D620N mutation in *VPS35* and describe their clinical features.

## Patients and Methods

### Subjects

The study was approved by the ethics committee of Juntendo University, and all subjects gave written

informed consent to participate in the genetic research. The study subjects were 308 Japanese patients (300 index patients) with ADPD (age at disease onset [AAO; mean  $\pm$  SD],  $51.1 \pm 11.7$  years; range, 8–83 years; female/male [F/M] ratio, 1.35) and 433 Japanese SPD patients (AAO,  $47.2 \pm 12.9$  years; range, 5–88 years; F/M ratio, 1.09) selected from the gene bank of Juntendo University. Some of the selected subjects had been confirmed negative for *SNCA*, *PARK2*, *PINK1*, *PARK7*, *LRRK2*, and *PLA2G6* mutations.<sup>9–14</sup> From the same gene bank, we also selected 579 healthy Japanese subjects without a family history of parkinsonism (age at sampling,  $58.0 \pm 9.3$  years; range, 23–89 years; F/M ratio, 1.54). The criteria for the diagnosis of PD were adopted by the participating neurologists and were established based on the United Kingdom Parkinson's Disease Society Brain Bank.<sup>15</sup>

### Genetic Analysis


Genomic DNA was extracted from peripheral blood using a standard protocol. Patients with ADPD and SPD were examined for the following 7 variants: p.M57I (exon 3), p.I241M (exon 7), p.P316S (exon 9), p.R524W (exon 13), p.D620N (exon 15), p.A737V (exon 16), and p.L774M (exon 17) of *VPS35* (RefSeq accession number NM\_018206.4). PCR direct sequencing was performed using a BigDye Terminator v1.1 Cycle Sequencing kit and 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA) or 3730 DNA Analyzer (Applied Biosystems). In addition, SPD patients and control subjects were also genotyped for c.1858G>A (p.D620N) mutation by high-resolution melting (HRM) analysis using LightScanner and LCGreen plus (Idaho Technology, Salt Lake City, UT). HRM analysis was performed using a previously described protocol<sup>16</sup> and the following primers: forward, GAGGATGGTTGGTCCCTTGAA; reverse, TGCCAATGATCAAGGTGATG. All exons of *VPS35* were also analyzed in patients with the p.D620N mutation using the method described previously.<sup>3</sup>

Haplotype analysis of the *VPS35* flanking region was performed using 3130 Genetic analyzer and GeneMapper software (Applied Biosystems, Foster City, CA). To adjust the size of PCR products, we also genotyped Centre d'Étude du Polymorphisme Humain (CEPH) control samples (1331-01 and 1331-02) for comparison of haplotypes with previously reported patients carrying the p.D620N mutation. The sequences of the PCR primers were reported previously.<sup>3</sup>

## Results

### Detection of p.D620N Mutation

We detected the heterozygous missense p.D620N mutation in 3 unrelated patients with ADPD and 1



**FIG. 1.** Pedigrees of families with the *VPS35* p.D620N mutation (open symbol, unaffected family member; closed symbol, affected member; arrow, proband; asterisk, individual analyzed for the p.D620N mutation and/or haplotype; forward slash through symbol, deceased individuals; square, male; circle, female; diamond, unspecified sex).

patient with SPD (Fig. 1). The p.D620N has been reported previously as a pathogenic mutation for familial PD.<sup>3,4,6</sup> This mutation was not found in 1158 control chromosomes. Patients carrying the p.D620N mutation did not have any other variants in all exons of *VPS35*. In our population, the incidence of the p.D620N mutation was 1.0% (3 of 300) in ADPD and 0.23% (1 of 433) in SPD. The remaining variants analyzed in this study were not identified in any patients.

Haplotype analysis demonstrated that the Japanese patients with the p.D620N mutation had different genotypes from those of white patients with the same mutation.<sup>3</sup> One disease allele was detected by analyzing patient AII-11 and his relatives. Patients AII-11 and BIII-8 in this study carried at least the same single allele of microsatellites in the flanking region of *VPS35* (Table 1). On the other hand, patients CII-3 and D had a different genotype of D16S3105, with a locus mapped very close to *VPS35*, compared with the disease allele of AII-11 (Table 1, boldface).

**TABLE 1.** Haplotype analysis of *VPS35* p.D620N mutation carriers

Microsatellite	Patient ID			
	AII-11	BIII-8	CII-3	D
D16S401	170	166/170	166/172	166/170
D16S3068	143	141/145	145/147	145/145
D16S753	272	272/268	268/276	264/268
<i>VPS35</i> p.D620N	A	A/G	A/G	A/G
Chr16_45.333M	294	294/298	294/300	294/304
D16S3105	191	191/189	189/193	187/187
Chr16_45.615M	147	147/147	147/145	147/145
Chr16_45.806M	246	246/238	246/244	246/244
Chr16_45.835M	237	237/237	237/237	237/237
Chr16_45.855M	212	212/210	210/210	210/216
D16S3044	195	195/195	195/197	197/197

Both alleles are shown when markers of phase could not be determined.

**TABLE 2.** Clinical features of patients with p.D620N mutation

	Patient ID			
	AII-11	BIII-8	CII-3	D
Age at disease onset (y)	62	55	34	42
Disease duration (y)	15	2	7	21
Resting tremor	+	+	+	+
Bradykinesia	+	+	+	+
Rigidity	+	+	+	+
Gait disturbance	+	–	–	+
Postural instability	+	–	–	+
Clinical response to levodopa	+	+	+	+
Wearing off	+	–	+	+
Asymmetry at onset	+	+	+	+
Orthostatic hypotension	+	–	–	–
Incontinence	+	–	–	–
Urinary urgency	–	–	–	–
Levodopa-induced dyskinesia	+	–	+	+
Sleep benefit	+	–	+	Unknown
Dystonia at onset	–	–	–	–
Hyperreflexia	–	–	–	–
Hallucination	–	–	–	–
Other psychosis	–	–	–	–
Dementia	+	–	–	–
Gaze palsy	–	–	–	–
Brain MRI	WNL	WNL	WNL	WNL
Cardiac MIBG scintigraphy	H/M ratio (E/L), 2.38/2.68; washout ratio, 4.15% <sup>a</sup>	Not performed	Not performed	Not performed

<sup>a</sup>MIBG scintigraphy was performed when AII-11 was 76 years old. WNL, within normal limit; H/M ratio, heart-to-mediastinum ratio; (E/L), early/late stage.

### Clinical Presentation

Table 2 summarizes the clinical features of the 4 *VPS35* mutation-positive patients. Patient AII-11 was a 77-year-old man who developed right upper limb rest tremor at age 62. At age 75, he underwent gastrostomy for progressive dysphagia, then developed cognitive dysfunction without hallucination. Single-photon emission computed tomography of cerebral blood flow showed no reduction in blood flow in the basal ganglia. His father and 4 of 8 siblings were diagnosed with PD (Fig. 1A) and presented levodopa-responsive typical parkinsonism: upper limb tremor and small-step gait. His nephew and niece were also diagnosed with PD, and the nephew developed parkinsonism in his early fifties. Patients BIII-8 and CII-3 both developed upper limb rest tremor at ages 34 and 55, respectively. The mother and aunts of patient BIII-8

and the father of patient CII-3 also developed PD (Fig. 1B, C). Patient D, who developed upper limb rest tremor at age 42, had no family history of PD. She underwent subthalamic nucleus deep brain stimulation (STN-DBS) at age 60 because of disabling motor fluctuation and dyskinesia refractory to pharmacological treatment. All affected patients were born to nonconsanguineous parents.

## Discussion

*VPS35* has been reported as the pathogenic gene for ADPD, and only 1 mutation, p.D620N, has been reported in several unrelated white families. To our knowledge, there have been no reports of Asian PD patients with *VPS35* mutations.<sup>3,8</sup> Based on this background, we set out in this study to determine the incidence of *VPS35* mutations in Japanese patients with PD. We detected the heterozygous p.D620N mutation of *VPS35* in 3 ADPD families and 1 SPD patient with East Asian ancestry. On the other hand, we could not conclude the pathogenicity of 6 other variants that had been reported as potentially pathogenic for PD because none of the variants was detected in our patients with PD.

The frequency of the p.D620N mutation in Japanese patients was 1.0% in ADPD and 0.23% in SPD. Although the exact frequency among whites is undetermined, the frequency is relatively higher in Japanese patients compared with that reported in previous studies (0%–1.22%).<sup>3,4,6,7,17</sup> Moreover, the frequency in Japanese patients also differs greatly from those of other Asian populations such as Taiwanese patients and mainland Chinese patients (0%).<sup>3,8</sup> Although the mutation frequency was expected to be lower than that of other pathogenic genes for ADPD, such as multiplication of *SNCA*<sup>9,18</sup> and point mutation of *LRRK2*,<sup>19–21</sup> *VPS35* may be one of the most important genes in Japanese PD. Because we screened for only 7 reported variants, we cannot determine the exact frequency of *VPS35* mutations in ADPD; we would need to analyze all 17 exons of *VPS35* in ADPD patients to screen for other variants and to assess the incidence of all disease-associated *VPS35* mutations.<sup>3,4</sup> Furthermore, we would need to perform mutational analysis for SPD patients, in addition to ADPD, to identify Asian population-specific variants, such as *LRRK2* p.G2385R, associated with susceptibility for PD.<sup>19</sup>

Based on haplotype analysis reported in previous studies, the substitution of *VPS35* c.1858G>A (p.D620N) occurs from independent mutational events.<sup>3</sup> We were able to determine the chromosomal phase only in patient AII-11 (family A). The p.D620N mutation possibly shared a common founder between Japanese ADPD families A and B; however, it was inconclusive because the phase of patient BIII-8 was

undetermined. On the other hand, the same p.D620N mutation probably occurred independently in patient CII-3 (family C) and patient D. By genotyping of D16S3105, which is located approximately 1.5 kb centromeric of *VPS35*, there were at least 3 different haplotypes in Japanese because families A and C and patient D (SPD) did not have the same alleles for this microsatellite. To determine the chromosomal phase of families B and C, detailed genetic analyses of other family members are needed in future studies. These results suggest the existence of 3 or more founders in Japanese patients, in addition to the reported white patients with the p.D620N mutation or de novo mutations, indicating that the p.D620N mutation site is a mutational hot spot in *VPS35* across different ethnic populations.

According to previous reports, the average AAO of patients with the *VPS35* mutation was 50–60 years ( $50.6 \pm 7.3$  years),<sup>3</sup> with a distinctive feature of a slightly younger AAO compared with patients with idiopathic PD. In our study, the AAO was nonspecific with a wide range between 30–70 years. Because the family history of patient D was unknown, she was categorized as SPD. With regard to *VPS35* mutation penetrance, it is incomplete from the results of a previous report.<sup>3</sup> Therefore, although the frequency is low, patients with p.D620N mutation could be found among SPD patients.

The clinical symptoms of our patients with *VPS35* mutation closely resembled the idiopathic PD form, with tremor-dominant dopa-responsive parkinsonism. Psychiatric problems were inconspicuous; however, dementia may occur in patients with a long disease course, similar to patient AII-11, who had PD for 15 years. Our patients with *VPS35* mutations had normal brain MRI and cardiac MIBG scintigraphy. There have been no definite pathological mutations of *VPS35* in the spectrum of LB disorders. On the basis of these results, patients with *VPS35* mutation could show comparatively benign disease course without widespread LB pathology.<sup>22,23</sup>

*VPS35* assembles into the retromer cargo-recognition complex that associates with the cytosolic face of the endosomes. The retromer mediates the retrograde transport of transmembrane cargo from the endosomes to the trans-Golgi network.<sup>5</sup> The p.D620N mutation of *VPS35* might cause impairment of interaction with other components of the retromer complex and impaired retrograde trafficking of recycling proteins,<sup>4</sup> similar to  $\alpha$ -synuclein and *LRRK2*, which are involved in vesicle trafficking.<sup>24,25</sup> Mutations in familial PD genes, including *VPS35*, may cause disruption of intracellular trafficking and lead to neurodegeneration. These findings suggest that impairment of intracellular trafficking systems is associated with the pathogenesis of PD. Although the association between the p.D620N mutation of *VPS35* and PD remains unknown, further functional studies might shed light on the pathogenesis

of VPS35 mutation and the effects of interaction with other known pathogenic gene products on PD.

In conclusion, we have reported Asian PD patients with the VPS35 p.D620N mutation. The p.D620N substitution may be a mutational hot spot across different ethnic populations. The frequency of VPS35 mutation was low in ADPD; however, it is relatively high in Japanese patients compared with that reported in other populations.<sup>3,4,6-8</sup> Based on the clinical features of patients with VPS35 mutation, VPS35 should be analyzed in patients with PD, especially ADPD or tremor-predominant PD. ■

**Acknowledgments:** We thank all the participants in this study.

## References

- Lang AE, Lozano AM. Parkinson's disease. First of two parts. *N Engl J Med* 1998;339:1044-1053.
- Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. *Hum Mol Genet* 2009;18:R48-R59.
- Vilariño-Güell C, Wider C, Ross OA, et al. VPS35 mutations in Parkinson disease. *Am J Hum Genet* 2011;89:162-167.
- Zimprich A, Benet-Pagès A, Struhal W, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. *Am J Hum Genet* 2011;89:168-175.
- Bonifacino JS, Hurley JH. Retromer. *Curr Opin Cell Biol* 2008;4:427-436.
- Sheerin UM, Charlesworth G, Bras J, et al. Screening for VPS35 mutations in Parkinson's disease. *Neurobiol Aging* 2012;4:838.e1-e5.
- Guella I, Soldà G, Cilia R, et al. The Asp620asn mutation in VPS35 is not a common cause of familial Parkinson's disease. *Mov Disord* 2012;27:800-801.
- Zhang Y, Chen S, Xiao Q, et al. Vacuolar protein sorting 35 Asp620Asn mutation is rare in the ethnic Chinese population with Parkinson's disease. *Parkinsonism Relat Disord* 2012;18:638-640.
- Nishioka K, Hayashi S, Farrer MJ, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. *Ann Neurol* 2006;59:298-309.
- Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature* 1998;392:605-608.
- Kumazawa R, Tomiyama H, Li Y, et al. Mutation analysis of the PINK1 gene in 391 patients with Parkinson disease. *Arch Neurol* 2008;65:802-808.
- Tomiyama H, Li Y, Yoshino H, et al. Mutation analysis for DJ-1 in sporadic and familial parkinsonism: screening strategy in parkinsonism. *Neurosci Lett* 2009;455:159-161.
- Tomiyama H, Li Y, Funayama M, et al. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. *Mov Disord* 2006;21:1102-1108.
- Yoshino H, Tomiyama H, Tachibana N, et al. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. *Neurology* 2010;75:1356-1361.
- Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry* 1992;55:181-184.
- Funayama M, Tomiyama H, Wu RM, et al. Rapid screening of ATP13A2 variant with high-resolution melting analysis. *Mov Disord* 2010;25:2434-2437.
- Lesage S, Condroyer C, Klebe S et al. Identification of VPS35 mutations replicated in French families with Parkinson disease. *Neurology* 2012;78:1449-1450.
- Ibáñez P, Lesage S, Janin S, et al. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. *Arch Neurol* 2009;66:102-108.
- Seki N, Takahashi Y, Tomiyama H, et al. Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease. *J Hum Genet* 2011;56:671-675.
- Di Fonzo A, Rohe C, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. *Lancet* 2005;365:412-415.
- Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. *Lancet* 2005;365:415-416.
- Orimo S, Amino T, Yokochi M, et al. Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2. *Mov Disord* 2005;10:1350-1353.
- Verstraeten A, Wauters E, Crosiers D, et al. Contribution of VPS35 genetic variability to LBD in the Flanders-Belgian population. *Neurobiol Aging* 2012;33:e11-e13.
- Caudle WM, Colebrooke RE, Emson PC, et al. Altered vesicular dopamine storage in Parkinson's disease: a premature demise. *Trends Neurosci* 2008;31:303-308.
- Berwick DC, Harvey K. LRRK2 signaling pathways: the key to unlocking neurodegeneration? *Trends Cell Biol* 2011;21:257-265.